mechanism	alcohol : it should be borne in mind that <e10> drug1 </e10> ingestion may increase the danger inherent in any intentional or unintentional <e21> drug2 </e21> overdosage .
mechanism	h2 _ receptor _ antagonists : <e10> drug1 </e10> coadministration leads to an increased peak plasma concentration and auc of <e20> drug2 </e20> , there is no effect on drug2 absorption when it is coadministered with ranitidine .
mechanism	a number of drugs , including <e10> drug1 </e10> , have been shown to displace <e20> drug2 </e20> from plasma protein ;
mechanism	cholestyramine and charcoal administration of <e10> drug1 </e10> or activated _ charcoal in patients ( n = 13 ) and volunteers ( n = 96 ) resulted in a rapid and significant decrease in plasma m1 ( the active metabolite of <e20> drug2 </e20> ) concentration .
mechanism	at higher than recommended doses , <e11> drug1 </e11> # mg administered once daily for # days increased plasma concentrations by 23 % as measured by auc0 - 24hr in patients receiving <e20> drug2 </e20> # to # mg / week for rheumatoid arthritis .
mechanism	urinary acidifying agents these agents ( <e10> drug1 </e10> , sodium _ acid _ phosphate , etc , ) increase the concentration of the ionized species of the <e20> drug2 </e20> molecule , thereby increasing urinary excretion .
mechanism	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma <e10> drug1 </e10> concentrations include : acute alcohol intake , amiodarone , chboramphenicol , chlordiazepoxide , <e20> drug2 </e20> , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , h2 - antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone
mechanism	results : during treatment with <e10> drug1 </e10> , there was a statistically significant decrease in the median of the total clearance of <e20> drug2 </e20> , from # ml / h to # ml / h , among the volunteers who received # mg / d .
mechanism	erythromycin and <e10> drug1 </e10> ( and possibly other macrolide _ antibiotics ) and tetracycline may increase <e20> drug2 </e20> absorption in patients who inactivate drug2 by bacterial metabolism in the lower intestine , so that digitalis intoxication may result .
mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of <e11> drug1 </e11> are the following : acetazolamide , azole _ antifungals , cimetidine , clarithromycin ( 1 ) , dalfopristin , danazol , delavirdine , diltiazem , erythromycin ( 1 ) , fluoxetine , fluvoxamine , grapefruit juice , isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease _ inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate ( 1 ) , verapamil , <e20> drug2 </e20> .
mechanism	erythromycin and clarithromycin ( and possibly other macrolide _ antibiotics ) and <e10> drug1 </e10> may increase <e20> drug2 </e20> absorption in patients who inactivate drug2 by bacterial metabolism in the lower intestine , so that digitalis intoxication may result .
mechanism	in another drug interaction study , co - administration of orally inhaled <e10> drug1 </e10> and oral <e20> drug2 </e20> , a potent inhibitor of cytochrome p450 3a4 , increased the exposure ( auc ) of des - drug1 by approximately # - fold at steady state , while levels of drug1 remained unchanged .
mechanism	in # other schizophrenic patients treated with oral drug2 and drug1 , discontinuation of <e10> drug1 </e10> produced a mean # - fold increase in <e20> drug2 </e20> concentrations .
mechanism	other potentially important drug interactions : benzodiazepines : benzodiazepines metabolized by hepatic oxidation ( e , g , , alprazolam , midazolam , <e10> drug1 </e10> elc , ) should be used with caution because the clearance of these drugs is likely to be reduced by <e20> drug2 </e20> .
mechanism	metoprolol - administration of # mg / day <e11> drug1 </e11> for # days in healthy volunteers resulted in a 50 % increase in cmax and 82 % increase in auc of the beta - adrenergic _ blocker <e20> drug2 </e20> ( given in a single dose of # mg ) .
mechanism	calcium _ antagonist s : after repeated co - administration of <e11> drug1 </e11> , the auc of <e20> drug2 </e20> was lowered by 28 % [ 90 % ci : 20 - 33 ] .
mechanism	ganciclovir : administration of <e11> drug1 </e11> # hours prior to or concurrent with oral <e20> drug2 </e20> was associated with a # ( 114 ) % increase in the steady - state auc of didanosine ( n = 12 ) .
mechanism	<e10> drug1 </e10> ( 200 mg once daily ) produced a 10 - fold increase in <e20> drug2 </e20> auc and a 4 - fold increase in cmax when co - administered with vardenafil ( 5 mg ) in healthy volunteers .
mechanism	ascorbic _ acid : doses of ascorbic _ acid ( <e10> drug1 </e10> ) # g / day have been reported to increase plasma concentration of <e22> drug2 </e22> by ~ 47 % , possibly by inhibiting conjugation ;
mechanism	on the basis of the metabolism of drug2 by cytochrome p450 3a4 , ketoconazole , itraconazole , <e10> drug1 </e10> , gemfibrozil , grapefruit juice , and other inhibitors of cytochrome p450 3a4 would be expected to lead to an increase in plasma <e20> drug2 </e20> concentrations .
mechanism	antacids and drug1 : antacids and <e10> drug1 </e10> can reduce absorption of <e20> drug2 </e20> ;
mechanism	in a study in which the # mg <e10> drug1 </e10> orally disintegrating tablet was administered with and without <e20> drug2 </e20> ( an anticholinergic _ agent with multiple effects on the gi tract ) to healthy volunteers , the auc of drug1 was 10 % lower and the cmax of drug1 was 20 % lower when the orally disintegrating tablet was given with drug2 compared to when it was given alone .
mechanism	drugs that induce cyp3a4 ( rifampicin ) racemic <e10> drug1 </e10> exposure was decreased 80 % by concomitant useof <e20> drug2 </e20> , a potent inducer of cyp3a4 .
mechanism	morphine : combination <e12> drug1 </e12> may increase the clearance of <e20> drug2 </e20> .
mechanism	multivalent cation - containing products : concurrent administration of a quinolone , including <e10> drug1 </e10> , with multivalent cation - containing products such as magnesium or aluminum antacids , <e20> drug2 </e20> , videx chewable / buffered tablets or pediatric powder , or products containing calcium , iron , or zinc may substantially decrease the absorption of drug1 , resulting in serum and urine levels considerably lower than desired .
mechanism	the plasma concentration of <e10> drug1 </e10> may increase when the drug is given concomitantly with hepatic enzyme inhibitors ( e , g , , cimetidine , fluoxetine ) and decrease by concomitant administration of hepatic enzyme inducers ( e , g , , barbiturates , <e20> drug2 </e20> ) , and adjustment of the dosage of drug1 may therefore be necessary .
mechanism	<e10> drug1 </e10> decreased the binding of <e20> drug2 </e20> by a net change of # % ( percentage increase in fdf , # % ) at # micromol / l ;
mechanism	plasma levels of several closely related <e12> drug1 </e12> have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors ( e , g , , cimetidine , fluoxetine ) and decreased by the concomitant administration of hepatic enzyme inducers ( e , g , , <e22> drug2 </e22> , phenytoin ) , and such an effect may be anticipated with cmi as well .
mechanism	serum concentration of digoxin and <e10> drug1 </e10> may increase when patients take <e22> drug2 </e22> .
mechanism	drugs which inhibit cyp 3a4 ( e , g , , ketoconazole , macrolide _ antibiotics such as <e10> drug1 </e10> ) have the potential to result in increased plasma concentrations of <e22> drug2 </e22> .
mechanism	although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 ( eg , calcium _ channel _ blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , <e10> drug1 </e10> , ergot _ derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with <e20> drug2 </e20> ;
mechanism	however , other published reports describe modest elevations ( less than two - fold ) of drug1 and metabolite concentrations when <e10> drug1 </e10> was taken with paroxetine , fluoxetine , and <e20> drug2 </e20> .
mechanism	when used in therapeutic doses , <e10> drug1 </e10> had a modest effect on the pharmacokinetics of atorvastatin , carbamazepine , cetirizine , didanosine , efavirenz , fluconazole , indinavir , midazolam , rifabutin , sildenafil , <e20> drug2 </e20> ( intravenous and oral ) , triazolam , trimethoprim / sulfamethoxazole or zidovudine .
mechanism	protease _ inhibitors : in vitro data indicate that <e10> drug1 </e10> and ritonavir markedly inhibit the metabolism of <e20> drug2 </e20> which can result in an increase in plasma drug2 levels and prolongation of the qt interval on the ecg .
mechanism	phenytoin : altered serum levels of <e10> drug1 </e10> ( increased and decreased ) have been reported in patients receiving concomitant <e20> drug2 </e20> .
mechanism	<e10> drug1 </e10> is reported to reduce hepatic metabolism of certain <e22> drug2 </e22> , thereby delaying elimination and increasing steady - state concentrations of these drugs .
mechanism	quinolone _ antibiotic s : videx should be administered at least # hours after or # hours before dosing with drug1 because plasma concentrations of <e10> drug1 </e10> are decreased when administered with antacids containing magnesium , <e20> drug2 </e20> , or aluminum .
mechanism	warfarin : <e12> drug1 </e12> , including enoxacin , decrease the clearance of <e20> drug2 </e20> , the less active isomer of racemic warfarin .
mechanism	quinidine , verapamil , amiodarone , propafenone , indomethacin , itraconazole , <e10> drug1 </e10> , and spironolactone raise the serum <e20> drug2 </e20> concentration due to a reduction in clearance and / or in volume of distribution of the drug , with the implication that digitalis intoxication may result .
mechanism	co - administration with <e10> drug1 </e10> or fluconazole had a modest effect on the pharmacokinetics of <e20> drug2 </e20> .
mechanism	levothyroxine _ sodium absorption : the following agents may bind and decrease absorption of <e10> drug1 </e10> from the gastrointestinal tract : <e20> drug2 </e20> , cholestyramine resin , colestipol _ hydrochloride , ferrous _ sulfate , sodium _ polystyrene _ sulfonate , soybean flour ( e , g , , infant formula ) , sucralfate .
mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of <e11> drug1 </e11> are the following : acetazolamide , azole _ antifungals , cimetidine , clarithromycin ( 1 ) , <e20> drug2 </e20> , danazol , delavirdine , diltiazem , erythromycin ( 1 ) , fluoxetine , fluvoxamine , grapefruit juice , isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease _ inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate ( 1 ) , verapamil , zileuton .
mechanism	although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 ( eg , calcium _ channel _ blockers , <e10> drug1 </e10> , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot _ derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with <e20> drug2 </e20> ;
mechanism	drug1 : <e10> drug1 </e10> has been reported to decrease the metabolism of certain <e22> drug2 </e22> by up to 60 % , leading to increased risk of corticosteroid side effects .
mechanism	in clinical trials , drug2 was used with digoxin , diuretics , anticoagulants , oral vasodilators , and supplemental oxygen , in a pharmacokinetic substudy in patients with congestive heart failure receiving <e10> drug1 </e10> or digoxin in whom therapy with <e21> drug2 </e21> was initiated , apparent oral clearance values for drug1 ( n = 23 ) and digoxin ( n = 30 ) were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
mechanism	tricyclic _ antidepressants ( amitriptyline , <e10> drug1 </e10> , nortriptyline ) : metabolism may be inhibited by <e22> drug2 </e22> , increasing plasma levels of antidepressant ;
mechanism	steady - state <e10> drug1 </e10> plasma concentrations were 3 - to 4 - fold higher than in the absence of <e20> drug2 </e20> .
mechanism	levothyroxine _ sodium absorption : the following agents may bind and decrease absorption of <e10> drug1 </e10> from the gastrointestinal tract : aluminum _ hydoxide , cholestyramine resin , colestipol _ hydrochloride , ferrous _ sulfate , <e20> drug2 </e20> , soybean flour ( e , g , , infant formula ) , sucralfate .
mechanism	non - nucleoside _ reverse _ transcriptase _ inhibitors ( nnrtis ) : <e10> drug1 </e10> may decrease plasma levels of <e22> drug2 </e22> ;
mechanism	ketoconazole : coadministration of <e10> drug1 </e10> ( 200 mg / day for # days ) with a 15 - mg single dose of <e20> drug2 </e20> increased the auc of drug2 and its active metabolite by 63 % and 77 % , respectively .
mechanism	binding to serum proteins : the following agents may either inhibit <e10> drug1 </e10> binding to serum proteins or alter the concentrations of serum binding proteins : androgens and related anabolic _ hormones , asparaginase , clofibrate , estrogens and estrogen - containing _ compounds , 5 - fluorouracil , furosemide , glucocorticoids , meclofenamic _ acid , mefenamic _ acid , methadone , perphenazine , <e20> drug2 </e20> , phenytoin , salicylates , tamoxifen .
mechanism	antibiotics : in vitro and / or in vivo data show that clarithromycin , <e10> drug1 </e10> , and troleandomycin markedly inhibit the metabolism of <e20> drug2 </e20> , which can result in an increase in plasma drug2 levels and prolongation of the qt interval on the ecg .
mechanism	antacids : in a single dose study ( n = 6 ) , ingestion of an antacid containing # - gram of <e10> drug1 </e10> with 500 - mg of <e20> drug2 </e20> increased the cmax and auc of drug2 by 125 % and 36 % , respectively , a number of compounds are inhibitors of cyp2c9 including fluconazole , lovastatin and trimethoprim .
mechanism	inhibitors or substrates of cyp2d6 ( i , e , , <e10> drug1 </e10> , selective _ serotonin _ reuptake _ inhibitors [ ssris ] ) may increase the plasma concentration of <e20> drug2 </e20> when administered concomitantly .
mechanism	hepatic enzyme inducers , inhibitors and substrates : drugs which induce cytochrome p450 3a4 ( cyp 3a4 ) enzyme activity ( e , g , , barbiturates , <e10> drug1 </e10> , carbamazepine , rifampin ) may enhance the metabolism of <e22> drug2 </e22> and require that the dosage of the corticosteroid be increased .
mechanism	<e12> drug1 </e12> ( amitriptyline , imipramine , nortriptyline ) : metabolism may be inhibited by <e22> drug2 </e22> , increasing plasma levels of antidepressant ;
mechanism	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma <e10> drug1 </e10> concentrations include : acute alcohol intake , amiodarone , chboramphenicol , chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , h2 - antagonists , halothane , isoniazid , methylphenidate , <e22> drug2 </e22> , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone
mechanism	additionally , higher than expected <e12> drug1 </e12> levels have been observed when they are begun in patients already taking <e20> drug2 </e20> .
mechanism	intravenous <e10> drug1 </e10> was shown to double the bioavailability of oral <e20> drug2 </e20> .
mechanism	<e10> drug1 </e10> significantly decreased the auc ( ss ) of <e20> drug2 </e20> by 82 % , but drug2 had no effect on rifampin pharmacokinetics .
mechanism	thus <e10> drug1 </e10> appeared to alter the renal excretion of both <e20> drug2 </e20> and creatinine , an endogenous marker of renal function .
mechanism	phenytoin : in post - marketing experience , there have been reports of both increases and decreases in <e10> drug1 </e10> levels with <e20> drug2 </e20> co - administration , leading to alterations in seizure control .
mechanism	<e10> drug1 </e10> produced only minor changes in the levels of <e20> drug2 </e20> and its metabolites .
mechanism	even so <e10> drug1 </e10> plasma concentrations in the presence of high doses of <e20> drug2 </e20> were almost 5 - fold lower than those seen in cyp 2d6 poor metabolizers suggesting that dose adjustment is not necessary .
mechanism	by decreasing the gastrointestinal absorption of drug2 , <e11> drug1 </e11> may decrease serum concentrations of <e20> drug2 </e20> and its metabolites , with a consequent possible decrease in anticonvulsant effect .
mechanism	in a single - dose crossover study examining lansoprazole # mg and omeprazole # mg each administered alone and concomitantly with drug2 # gram , absorption of the <e12> drug1 </e12> was delayed and their bioavailability was reduced by 17 % and 16 % , respectively , when administered concomitantly with <e20> drug2 </e20> .
mechanism	coadministration with compounds that are potent inducers of cyp3a4 ( eg , phenobarbital , phenytoin , dexamethasone , <e10> drug1 </e10> ) may result in decreased plasma levels of <e20> drug2 </e20> .
mechanism	oral contraceptives : <e10> drug1 </e10> , when given once daily for # days as a 100 - mg capsule with an oral contraceptive containing # mcg of <e20> drug2 </e20> and # mg of norethindrone , decreased the auc of drug2 by 43 % , and decreased the auc of norethindrone by 8 % ;
mechanism	oral contraceptives : coadministration of <e10> drug1 </e10> and an oral contraceptive increased auc values for <e20> drug2 </e20> and ethinyl _ estradiol by approximately 30 % and 20 % .
mechanism	antacids : concomitant administration of <e12> drug1 </e12> may reduce plasma levels of <e20> drug2 </e20> .
mechanism	probenecid : as with other <e12> drug1 </e12> , probenecid inhibits the renal excretion of <e20> drug2 </e20> , resulting in an approximate doubling in a , c , a 54 % increase in peak drug2 plasma levels , and a 50 % prolongation in the apparent elimination half - life .
mechanism	h2 - receptor _ antagonists : co - administration of a single dose of intravenously administered <e10> drug1 </e10> ( 20 mg ) reduced the oral absorption of a single # mg dose of <e20> drug2 </e20> administered following a meal , as evidenced by a 27 % decrease in mean cmax and a 22 % decrease in mean auc .
mechanism	ascorbic _ acid : doses of <e10> drug1 </e10> ( vitamin _ c ) # g / day have been reported to increase plasma concentration of <e22> drug2 </e22> by ~ 47 % , possibly by inhibiting conjugation ;
mechanism	anticonvulsants ( phenytoin ) : steady state plasma exposure ( auc ) of <e10> drug1 </e10> ( 40 mg bid for # days ) was decreased by 27 % when co - administered with multiple doses ( 300 mg qd for # days ) of <e20> drug2 </e20> ( a cyp 3a4 inducer ) .
mechanism	binding to serum proteins : the following agents may either inhibit <e10> drug1 </e10> binding to serum proteins or alter the concentrations of serum binding proteins : androgens and related anabolic _ hormones , asparaginase , clofibrate , estrogens and estrogen - containing _ compounds , 5 - fluorouracil , furosemide , glucocorticoids , meclofenamic _ acid , mefenamic _ acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , <e20> drug2 </e20> .
mechanism	however , a crossover study in healthy subjects receiving either <e11> drug1 </e11> # mg q , i , d , or # mg h , s , concomitantly with a # mg b , i , d , dosage of theophylline ( <e21> drug2 </e21> , key pharmaceuticals , inc , ) demonstrated less alteration in steady - state theophylline peak serum levels with the # mg h , s , regimen , particularly in subjects aged # years and older .
mechanism	for example , since <e10> drug1 </e10> may reduce the gastrointestinal absorption of both the oral anticoagulants and <e22> drug2 </e22> , the net effects are unpredictable .
mechanism	<e10> drug1 </e10> caused a statistically significant increase in plasma exposures of r - warfarin and <e20> drug2 </e20> ( 12 % and 15 % , respectively ) , and in the pharmacodynamic effects ( prothrombin time , measured as inr ) of warfarin .
mechanism	phenytoin , nicotine , and <e10> drug1 </e10> may decrease <e20> drug2 </e20> plasma levels , resulting in a decrease in effectiveness of a previously effective drug2 dose .
mechanism	plasma levels of several closely related tricyclic _ antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors ( e , g , , cimetidine , fluoxetine ) and decreased by the concomitant administration of hepatic enzyme inducers ( e , g , , barbiturates , <e10> drug1 </e10> ) , and such an effect may be anticipated with <e20> drug2 </e20> as well .
mechanism	antacids or <e10> drug1 </e10> substantially interfere with the absorption of some <e22> drug2 </e22> , resulting in low urine levels .
mechanism	protease _ inhibitors : amprenavir , <e10> drug1 </e10> , nelfinavir , and ritonavir have been shown to decrease plasma levels of <e22> drug2 </e22> ;
mechanism	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma <e10> drug1 </e10> concentrations include : acute alcohol intake , amiodarone , chboramphenicol , chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , <e20> drug2 </e20> , h2 - antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone
mechanism	in vitro , <e10> drug1 </e10> appears to be displaced from its binding sites by <e20> drug2 </e20> .
mechanism	<e10> drug1 </e10> diminished binding of <e20> drug2 </e20> by a net change of # % ( percentage increase in fdf , # % ) at # micromol / l .
mechanism	the absorption of oral <e10> drug1 </e10> is significantly reduced by the concomitant administration of an antacid containing aluminum and <e20> drug2 </e20> .
mechanism	this observed increase in the bioavailability of drug2 may be due to transport - related effects , such as p - glycoprotein , in vivo animal studies also suggest that in addition to enhancing absorption , <e10> drug1 </e10> decreases <e20> drug2 </e20> gastrointestinal secretion , while erythromycin may also decrease biliary excretion .
mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of <e11> drug1 </e11> are the following : acetazolamide , azole _ antifungals , cimetidine , clarithromycin ( 1 ) , dalfopristin , danazol , delavirdine , diltiazem , erythromycin ( 1 ) , <e20> drug2 </e20> , fluvoxamine , grapefruit juice , isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease _ inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate ( 1 ) , verapamil , zileuton .
mechanism	antibiotics : in vitro and / or in vivo data show that clarithromycin , erythromycin , and <e10> drug1 </e10> markedly inhibit the metabolism of <e20> drug2 </e20> , which can result in an increase in plasma drug2 levels and prolongation of the qt interval on the ecg .
mechanism	although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 ( eg , calcium _ channel _ blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot _ derivatives , pimozide , carbamazepine , fentanyl , <e10> drug1 </e10> , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with <e20> drug2 </e20> ;
mechanism	praziquantel : in the fed state , <e10> drug1 </e10> ( 40 mg / kg ) increased mean maximum plasma concentration and area under the curve of <e20> drug2 </e20> by about 50 % in healthy subjects ( n = 10 ) compared with a separate group of subjects ( n = 6 ) given albendazole alone .
mechanism	methotrexate renal tubular transport of <e10> drug1 </e10> may be inhibited by concomitant administration of <e20> drug2 </e20> , potentially leading to increased plasma levels of drug1 .
mechanism	however , the peak plasma level of <e10> drug1 </e10> was reduced by approximately 20 % when taking <e20> drug2 </e20> due to a slight delay in the absorption of drug1 .
mechanism	ethosuximide : <e12> drug1 </e12> may delay intestinal absorption of <e20> drug2 </e20> .
mechanism	steady - state serum concentrations of <e12> drug1 </e12> are reported to fluctuate significantly when <e20> drug2 </e20> is either added or deleted from the drug regimen .
mechanism	<e10> drug1 </e10> interferes with the metabolism of <e20> drug2 </e20> resulting in a 42 % to 74 % dose - related decrease in drug2 clearance and a subsequent 260 % to 350 % increase in serum drug2 levels .
mechanism	particular caution should be observed with digitalis _ preparations since there are conflicting results for the effect of <e10> drug1 </e10> on the availability of digoxin and <e20> drug2 </e20> .
mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of <e11> drug1 </e11> are the following : acetazolamide , azole _ antifungals , cimetidine , clarithromycin ( 1 ) , dalfopristin , danazol , delavirdine , diltiazem , erythromycin ( 1 ) , fluoxetine , fluvoxamine , grapefruit juice , isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , <e22> drug2 </e22> , propoxyphene , quinine , quinupristin , troleandomycin , valproate ( 1 ) , verapamil , zileuton .
mechanism	multivalent cation - containing products : concurrent administration of a <e12> drug1 </e12> , including ciprofloxacin , with multivalent cation - containing products such as magnesium or aluminum antacids , sucralfate , videx chewable / buffered tablets or pediatric powder , or products containing calcium , iron , or <e20> drug2 </e20> may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .
mechanism	when used in therapeutic doses , <e10> drug1 </e10> had a modest effect on the pharmacokinetics of atorvastatin , carbamazepine , cetirizine , didanosine , efavirenz , fluconazole , indinavir , midazolam , rifabutin , sildenafil , theophylline ( intravenous and oral ) , triazolam , <e20> drug2 </e20> / sulfamethoxazole or zidovudine .
mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of <e11> drug1 </e11> are the following : acetazolamide , azole _ antifungals , cimetidine , clarithromycin ( 1 ) , dalfopristin , danazol , delavirdine , diltiazem , erythromycin ( 1 ) , fluoxetine , fluvoxamine , grapefruit juice , isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease _ inhibitors , propoxyphene , quinine , quinupristin , <e20> drug2 </e20> , valproate ( 1 ) , verapamil , zileuton .
mechanism	drugs which induce cyp3a4 activity ( eg , <e10> drug1 </e10> , rifampin , rifabutin ) would be expected to increase the clearance of <e20> drug2 </e20> resulting in lowered plasma concentrations .
mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of <e11> drug1 </e11> are the following : acetazolamide , azole _ antifungals , cimetidine , <e20> drug2 </e20> ( 1 ) , dalfopristin , danazol , delavirdine , diltiazem , erythromycin ( 1 ) , fluoxetine , fluvoxamine , grapefruit juice , isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease _ inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate ( 1 ) , verapamil , zileuton .
mechanism	antacids and sucralfate : sucralfate and antacids containing magnesium or aluminum , as well as formulations containing divalent and trivalent cations such as <e11> drug1 </e11> ( didanosine ) , chewable / buffered tablets or the pediatric powder for oral solution can form chelation complexes with <e20> drug2 </e20> and interfere with its bioavailability .
mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of <e11> drug1 </e11> are the following : acetazolamide , azole _ antifungals , cimetidine , clarithromycin ( 1 ) , dalfopristin , danazol , delavirdine , diltiazem , erythromycin ( 1 ) , fluoxetine , fluvoxamine , grapefruit juice , isoniazid , itraconazole , ketoconazole , <e20> drug2 </e20> , nefazodone , niacinamide , nicotinamide , protease _ inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate ( 1 ) , verapamil , zileuton .
mechanism	urinary alkalinizing agents ( <e10> drug1 </e10> , some thiazides ) increase the concentration of the non - ionized species of the <e20> drug2 </e20> molecule , thereby decreasing urinary excretion .
mechanism	in a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy , free <e10> drug1 </e10> may be decreased when <e22> drug2 </e22> are started thus increasing thyroid requirements .
mechanism	capsules <e11> drug1 </e11> # mg t , i , d , produced a clinically relevant elevation of plasma <e20> drug2 </e20> and reduction in renal drug2 clearance in psychiatric patients and normal subjects with steady state plasma drug2 concentrations .
mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of <e11> drug1 </e11> are the following : acetazolamide , azole _ antifungals , cimetidine , clarithromycin ( 1 ) , dalfopristin , danazol , delavirdine , diltiazem , erythromycin ( 1 ) , fluoxetine , fluvoxamine , grapefruit juice , isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease _ inhibitors , <e20> drug2 </e20> , quinine , quinupristin , troleandomycin , valproate ( 1 ) , verapamil , zileuton .
mechanism	methotrexate : <e10> drug1 </e10> may reduce the excretion of <e20> drug2 </e20> .
mechanism	<e12> drug1 </e12> , phenytoin , or rifampin increased metabolic clearance of <e20> drug2 </e20> because of the induction of hepatic enzymes .
mechanism	the clearance of <e12> drug1 </e12> may be increased with concurrent use of <e22> drug2 </e22> .
mechanism	1 - nc denotes a mean change of less than 10 % 2 - pediatrics 3 - mean increase in adults at high drug2 doses in vivo , the plasma levels of <e10> drug1 </e10> increased by up to 40 % , when <e21> drug2 </e21> was given at doses above # mg / day .
mechanism	interactions for vitamin _ d analogues ( vitamin _ d2 , vitamin _ d3 , calcitriol , and calcidiol ) : drug1 : <e10> drug1 </e10> has been reported to reduce intestinal absorption of <e22> drug2 </e22> ;
mechanism	colestipol : plasma concentrations of drug2 decreased approximately 25 % when <e10> drug1 </e10> and <e20> drug2 </e20> were coadministered .
mechanism	drug1 and kaolin : <e12> drug1 </e12> and kaolin can reduce absorption of <e20> drug2 </e20> ;
mechanism	inhibitors of cyp3a4 ( eg , ketoconazole ) or cyp2d6 ( eg , <e10> drug1 </e10> , fluoxetine , or paroxetine ) can inhibit <e20> drug2 </e20> elimination and cause increased blood levels .
mechanism	although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 ( eg , calcium _ channel _ blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot _ derivatives , pimozide , carbamazepine , <e10> drug1 </e10> , al drug1 , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with <e20> drug2 </e20> ;
mechanism	<e10> drug1 </e10> : may increase plasma concentration of <e22> drug2 </e22> , possibly by inhibiting conjugation .
mechanism	protein binding in vitro , <e10> drug1 </e10> interferes minimally or not at all with the protein binding of <e20> drug2 </e20> ( 20 % decrease in binding ) , tolbutamide , prednisolone ( 10 % decrease in binding ) , or warfarin .
mechanism	plasma levels of several closely related tricyclic _ antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors ( e , g , , <e10> drug1 </e10> , fluoxetine ) and decreased by the concomitant administration of hepatic enzyme inducers ( e , g , , barbiturates , phenytoin ) , and such an effect may be anticipated with <e20> drug2 </e20> as well .
mechanism	binding to serum proteins : the following agents may either inhibit <e10> drug1 </e10> binding to serum proteins or alter the concentrations of serum binding proteins : androgens and related anabolic _ hormones , asparaginase , clofibrate , <e22> drug2 </e22> and estrogen - containing _ compounds , 5 - fluorouracil , furosemide , glucocorticoids , meclofenamic _ acid , mefenamic _ acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen .
mechanism	dicumarol : it has been reported that <e10> drug1 </e10> prolongs the half - life of the anticoagulant , <e20> drug2 </e20> .
mechanism	antifungals : in vitro and / or in vivo data indicate that <e10> drug1 </e10> , itraconazole , and oral ketoconazole markedly inhibit the metabolism of <e20> drug2 </e20> , which can result in an increase in plasma drug2 levels and prolongation of the qt interval on the ecg .
mechanism	coadministration with <e10> drug1 </e10> increased exposure of <e20> drug2 </e20> ( auc ) by 46 % .
mechanism	multivalent cation - containing products : concurrent administration of a <e12> drug1 </e12> , including ciprofloxacin , with multivalent cation - containing products such as magnesium or aluminum antacids , <e20> drug2 </e20> , videx chewable / buffered tablets or pediatric powder , or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .
mechanism	when used in therapeutic doses , <e10> drug1 </e10> had a modest effect on the pharmacokinetics of atorvastatin , carbamazepine , cetirizine , didanosine , efavirenz , fluconazole , indinavir , midazolam , rifabutin , sildenafil , theophylline ( intravenous and oral ) , triazolam , trimethoprim / sulfamethoxazole or <e20> drug2 </e20> .
mechanism	concomitant administration of fenofibrate ( equivalent to 145mg <e11> drug1 </e11> ) with <e20> drug2 </e20> ( 40 mg ) once daily for # days has been shown to increase the mean cmax and auc values for drug2 by 36 % ( range from 69 % decrease to 321 % increase ) and 28 % ( range from 54 % decrease to 128 % increase ) , respectively , and for # - hydroxy - iso - drug2 by 55 % ( range from 32 % decrease to 314 % increase ) and 39 % ( range from 24 % decrease to 261 % increase ) , respectively in # healthy adults .
mechanism	in healthy subjects receiving <e10> drug1 </e10> ( 1 gm daily ) for one week , plasma <e20> drug2 </e20> levels increased by about 30 % and half - life increased by about 10 % .
mechanism	plasma exposure ( auc ) to <e10> drug1 </e10> was increased 62 % when coadministered with <e20> drug2 </e20> and 38 % when coadministered with ketoconazole .
mechanism	probenecid : as with other b - lactams , the renal excretion of <e10> drug1 </e10> is inhibited by <e20> drug2 </e20> .
mechanism	caffeine theobromine <e10> drug1 </e10> , like other quinolones , may inhibit the metabolism of <e20> drug2 </e20> and theobromine .
mechanism	the elimination half life of midazolam and <e10> drug1 </e10> also increased ( # # fold ) during coadministration with <e20> drug2 </e20> .
mechanism	in a study in which the # mg drug1 orally disintegrating tablet was administered with and without drug2 ( an anticholinergic _ agent with multiple effects on the gi tract ) to healthy volunteers , the auc of drug1 was 10 % lower and the cmax of <e10> drug1 </e10> was 20 % lower when the orally disintegrating tablet was given with <e20> drug2 </e20> compared to when it was given alone .
mechanism	the following are examples of drugs known to inhibit the metabolism of other related <e12> drug1 </e12> , presumably through inhibition of cyp3a : nefazodone , fluvoxamine , cimetidine , diltiazem , isoniazide , and some <e22> drug2 </e22> .
mechanism	since zarontin ( drug1 ) may interact with concurrently administered antiepileptic _ drugs , periodic serum level determinations of these drugs may be necessary ( eg , <e10> drug1 </e10> may elevate <e20> drug2 </e20> serum levels and valproic _ acid has been reported to both increase and decrease drug1 levels ) .
mechanism	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma <e10> drug1 </e10> concentrations include : acute alcohol intake , amiodarone , chboramphenicol , chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , <e22> drug2 </e22> , ethosuximide , fluoxetine , h2 - antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone
mechanism	barbiturates , phenytoin , or <e10> drug1 </e10> increased metabolic clearance of <e20> drug2 </e20> because of the induction of hepatic enzymes .
mechanism	drug1 , including oral contraceptives : <e12> drug1 </e12> may decrease the hepatic metabolism of certain <e22> drug2 </e22> , thereby increasing their effect .
mechanism	<e11> drug1 </e11> administration to three cancer patients over a dose range of # mg to # mg led to a dose - dependent inhibition of <e20> drug2 </e20> elimination # the effect of alternate - day administration of # mg of drug1 on drug metabolism in ms patients is unknown .
mechanism	because <e10> drug1 </e10> reduces the clearance of both <e20> drug2 </e20> and its active metabolite , n - desmethyl drug2 , there is a strong likelihood of substantial accumulation of both species during chronic co - administration .
mechanism	oral contraceptives : coadministration of <e10> drug1 </e10> and an oral contraceptive increased auc values for norethindrone and <e20> drug2 </e20> by approximately 30 % and 20 % .
mechanism	phenytoin : population pharmacokinetic analyses indicate that <e10> drug1 </e10> clearance is 60 % greater in patients taking <e20> drug2 </e20> with or without other enzyme - inducing aeds .
mechanism	[ the effect of drug1 on the renal excretion of verografin and drug2 in dogs ] the intravenous injection of <e10> drug1 </e10> in a dose of # mg / kg enhanced verografine and <e20> drug2 </e20> excretion in chronic canine experiments .
mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of <e11> drug1 </e11> are the following : acetazolamide , azole _ antifungals , cimetidine , clarithromycin ( 1 ) , dalfopristin , danazol , delavirdine , diltiazem , erythromycin ( 1 ) , fluoxetine , fluvoxamine , grapefruit juice , isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , <e20> drug2 </e20> , nicotinamide , protease _ inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate ( 1 ) , verapamil , zileuton .
mechanism	when drug2 is co - administered with drug1 ( 500 mg p , o , every # hours ) , <e10> drug1 </e10> competes for active tubular secretion and reduces the renal clearance of <e20> drug2 </e20> .
mechanism	amphotericin , foscarnet , and aminoglycosides : drugs such as amphotericin , <e10> drug1 </e10> , and aminoglycosides may increase the risk of developing peripheral neuropathy or other hivid - associated adverse events by interfering with the renal clearance of <e20> drug2 </e20> ( thereby raising systemic exposure ) .
mechanism	protein binding in vitro , <e10> drug1 </e10> interferes minimally or not at all with the protein binding of salicylic _ acid ( 20 % decrease in binding ) , tolbutamide , prednisolone ( 10 % decrease in binding ) , or <e20> drug2 </e20> .
mechanism	phenobarbital : it appears that <e10> drug1 </e10> may reduce plasma <e20> drug2 </e20> concentrations .
mechanism	this study demonstrated that the potent cytochrome p450 enzyme - inducer <e10> drug1 </e10> did indeed have a marked effect on the metabolism of <e20> drug2 </e20> , resulting in a 5 - fold increase in clearance when administered concomitantly to patients with dsm - iv - diagnosed schizophrenia , schizoaffective disorder , or bipolar disorder .
mechanism	on the basis of the metabolism of drug2 by cytochrome p450 3a4 , ketoconazole , itraconazole , erythromycin , <e10> drug1 </e10> , grapefruit juice , and other inhibitors of cytochrome p450 3a4 would be expected to lead to an increase in plasma <e20> drug2 </e20> concentrations .
mechanism	drugs that induce hepatic enzymes such as phenobarbital , phenytoin and <e10> drug1 </e10> may increase the clearance of <e22> drug2 </e22> and may require increases in corticosteroid dose to achieve the desired response .
mechanism	concomitant administration of <e10> drug1 </e10> doubled the auc for <e20> drug2 </e20> .
mechanism	when used in therapeutic doses , <e10> drug1 </e10> had a modest effect on the pharmacokinetics of atorvastatin , carbamazepine , cetirizine , didanosine , efavirenz , fluconazole , <e20> drug2 </e20> , midazolam , rifabutin , sildenafil , theophylline ( intravenous and oral ) , triazolam , trimethoprim / sulfamethoxazole or zidovudine .
mechanism	agents that induce cyp3a4 ( eg , <e10> drug1 </e10> ) could cause an increase in <e20> drug2 </e20> clearance and lower blood levels .
mechanism	the oral bioavailability of <e10> drug1 </e10> is reduced by 60 % with coadministration of <e20> drug2 </e20> .
mechanism	drug1 : <e10> drug1 </e10> may inhibit both synthetic and catabolic enzymes of <e22> drug2 </e22> .
mechanism	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma <e10> drug1 </e10> concentrations include : acute alcohol intake , amiodarone , chboramphenicol , chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , h2 - antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , <e22> drug2 </e22> , succinimides , sulfonamides , tolbutamide , trazodone
mechanism	although no clinical studies have been conducted , it is likely that the metabolism of <e10> drug1 </e10> may be affected by the known cyp3a4 inducers ( such as phenytoin , phenobarbital , rifampin ) , cyp3a4 inhibitors ( azole antimycotics e , g , , <e20> drug2 </e20> ;
mechanism	antifungals : in vitro and / or in vivo data indicate that fluconazole , <e10> drug1 </e10> , and oral ketoconazole markedly inhibit the metabolism of <e20> drug2 </e20> , which can result in an increase in plasma drug2 levels and prolongation of the qt interval on the ecg .
mechanism	binding to serum proteins : the following agents may either inhibit <e10> drug1 </e10> binding to serum proteins or alter the concentrations of serum binding proteins : androgens and related anabolic _ hormones , asparaginase , <e20> drug2 </e20> , estrogens and estrogen - containing _ compounds , 5 - fluorouracil , furosemide , glucocorticoids , meclofenamic _ acid , mefenamic _ acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen .
mechanism	antacids containing aluminum _ hydroxide and <e10> drug1 </e10> reduce the oral absorption of <e20> drug2 </e20> by 75 % .
mechanism	drug1 : <e10> drug1 </e10> has been demonstrated to interfere with the elimination of other <e22> drug2 </e22> .
mechanism	drugs metabolized by cytochrome p450 enzymes the drug interaction study evaluating the effect of drug1 on drug2 indicates that <e10> drug1 </e10> inhibits <e20> drug2 </e20> metabolism , which is mediated by cyp1a2 .
mechanism	protein binding in vitro , <e10> drug1 </e10> interferes minimally or not at all with the protein binding of salicylic _ acid ( 20 % decrease in binding ) , tolbutamide , <e20> drug2 </e20> ( 10 % decrease in binding ) , or warfarin .
mechanism	drug1 : <e10> drug1 </e10> may enhance the metabolic clearance of <e22> drug2 </e22> , resulting in decreased blood levels and lessened physiologic activity , thus requiring an increase in corticosteroid dosage .
mechanism	drug interactions with antacids administration of # mg of <e10> drug1 </e10> ( 2 x # mg capsule ) within # minutes of an aluminum and magnesium containing <e22> drug2 </e22> ( maalox ) decreased fexofenadine auc by 41 % and cmax by 43 % .
mechanism	methotrexate : <e10> drug1 </e10> , as well as other nonsteroidal _ anti - inflammatory _ drugs , probably reduces the tubular secretion of <e20> drug2 </e20> based on in vitro studies in rabbit kidney slices .
mechanism	in a study of # male subjects ( ages # to # years ) who were extensive metabolizers of the cyp2d6 isoenzyme , daily doses of <e10> drug1 </e10> given as # mg twice daily followed by a single dose of # mg <e20> drug2 </e20> increased the cmax , auc , and t1 / 2 of drug2 by an average of approximately 2 - , 5 - and 2 - fold , respectively .
mechanism	the absorption of oral <e10> drug1 </e10> is significantly reduced by the concomitant administration of an antacid containing <e20> drug2 </e20> and magnesium .
mechanism	when <e10> drug1 </e10> was administered ( at a dose of # mg bid ) in conjunction with a single 50 - mg dose of <e20> drug2 </e20> , a cyp2d6 substrate , the auc of drug2 increased 3 - fold .
mechanism	multivalent cation - containing products : concurrent administration of a quinolone , including <e10> drug1 </e10> , with multivalent cation - containing products such as magnesium or aluminum <e22> drug2 </e22> , sucralfate , videx chewable / buffered tablets or pediatric powder , or products containing calcium , iron , or zinc may substantially decrease the absorption of drug1 , resulting in serum and urine levels considerably lower than desired .
mechanism	drugs that cause significant sustained elevation in gastric ph ( histamine _ h2 - receptor _ antagonists such as <e10> drug1 </e10> or cimetidine ) may reduce plasma concentrations of <e21> drug2 </e21> and therefore potentially may reduce efficacy .
mechanism	the interaction is a consequence of blocking hepatic metabolism of <e10> drug1 </e10> by <e20> drug2 </e20> , a highly potent cyp3a4 inhibitor , which also inhibits cyp2c9 .
mechanism	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma <e10> drug1 </e10> concentrations include : acute alcohol intake , amiodarone , chboramphenicol , chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , h2 - antagonists , halothane , isoniazid , methylphenidate , phenothiazines , <e20> drug2 </e20> , salicylates , succinimides , sulfonamides , tolbutamide , trazodone
mechanism	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma <e10> drug1 </e10> concentrations include : acute alcohol intake , amiodarone , chboramphenicol , chlordiazepoxide , cimetidine , <e20> drug2 </e20> , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , h2 - antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone
mechanism	theophylline : <e10> drug1 </e10> is a competitive inhibitor of the metabolism of <e20> drug2 </e20> .
mechanism	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma <e10> drug1 </e10> concentrations include : acute alcohol intake , amiodarone , chboramphenicol , chlordiazepoxide , cimetidine , diazepam , <e20> drug2 </e20> , disulfiram , estrogens , ethosuximide , fluoxetine , h2 - antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone
mechanism	plasma levels of several closely related <e12> drug1 </e12> have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors ( e , g , , cimetidine , <e20> drug2 </e20> ) and decreased by the concomitant administration of hepatic enzyme inducers ( e , g , , barbiturates , phenytoin ) , and such an effect may be anticipated with cmi as well .
mechanism	for example , since <e10> drug1 </e10> may reduce the gastrointestinal absorption of both the oral <e22> drug2 </e22> and vitamin _ k , the net effects are unpredictable .
mechanism	benzodiazepines : combination <e12> drug1 </e12> may decrease the clearance of some benzodiazepines ( alprazolam , chlordiazepoxide , <e20> drug2 </e20> ) and increase the clearance of others ( lorazepam , oxazepam , temazepam ) .
mechanism	metoclopramide : bioavailability is mildly reduced ( approximately 10 % ) when <e10> drug1 </e10> and <e20> drug2 </e20> are coadministered .
mechanism	multivalent cation - containing products : concurrent administration of a quinolone , including <e10> drug1 </e10> , with multivalent cation - containing products such as magnesium or <e20> drug2 </e20> antacids , sucralfate , videx chewable / buffered tablets or pediatric powder , or products containing calcium , iron , or zinc may substantially decrease the absorption of drug1 , resulting in serum and urine levels considerably lower than desired .
mechanism	human pharmacokinetics data indicate that oral <e10> drug1 </e10> potently inhibits the metabolism of <e20> drug2 </e20> resulting in a mean eight - fold increase in auc of drug2 .
mechanism	plasma exposure of <e10> drug1 </e10> ( 10 mg bid ) was increased by 28 % following administration of <e20> drug2 </e20> ( 40 mg bid ) for # days , while plasma exposure of drug2 ( 40 mg bid ) was not substantially increased following administration of drug1 ( 10 mg bid ) for # days .
mechanism	anticonvulsants ( carbamazepine , felbamate , <e10> drug1 </e10> , phenytoin , topiramate ) : increase the metabolism of ethinyl _ estradiol and / or some <e22> drug2 </e22> , leading to possible decrease in contraceptive effectiveness .
mechanism	in vitro data suggest that <e10> drug1 </e10> also markedly inhibits the biotransformation system mainly responsible for the metabolism of <e20> drug2 </e20> ;
mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of <e11> drug1 </e11> are the following : acetazolamide , azole _ antifungals , cimetidine , clarithromycin ( 1 ) , dalfopristin , danazol , delavirdine , diltiazem , erythromycin ( 1 ) , fluoxetine , fluvoxamine , grapefruit juice , isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease _ inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate ( 1 ) , <e20> drug2 </e20> , zileuton .
mechanism	antacids increase the rate of absorption of <e10> drug1 </e10> , while <e20> drug2 </e20> decreases it .
mechanism	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma <e10> drug1 </e10> concentrations include : acute alcohol intake , amiodarone , chboramphenicol , <e20> drug2 </e20> , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , h2 - antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone
mechanism	in a ten - subject study , coadministration of <e10> drug1 </e10> ( 120 mg bid ) with <e20> drug2 </e20> resulted in a 3 - 4 times increase in mean drug2 auc and cmax vs , drug2 alone ;
mechanism	warfarin : co - administration of <e10> drug1 </e10> # mg b , i , d , for # days decreased the plasma concentrations of both <e20> drug2 </e20> ( a cyp2c9 substrate ) and r - warfarin ( a cyp3a4 substrate ) by # and 38 % , respectively .
mechanism	rifampin : when a single 375 - mg dose of <e10> drug1 </e10> was administered on day9 of a 14 - day regimen of # mg / day of <e20> drug2 </e20> , a strong cyp3a4 inducer , the auc of aprepitant decreased approximately 11 - fold and the mean terminal half - life decreased approximately 3 - fold .
mechanism	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma <e10> drug1 </e10> concentrations include : acute alcohol intake , <e20> drug2 </e20> , chboramphenicol , chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , h2 - antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone
mechanism	coadministration with compounds that are potent inducers of cyp3a4 ( eg , phenobarbital , phenytoin , <e10> drug1 </e10> , carbamazepine ) may result in decreased plasma levels of <e20> drug2 </e20> .
mechanism	carbamazepine : carbamazepine causes an approximate 50 % increase in the clearance of drug2 at steady state and , therefore , the addition of <e10> drug1 </e10> results in an approximate 40 % decrease in the steady - state trough concentrations of <e21> drug2 </e21> as compared to the same dose of drug2 given as monotherapy .
mechanism	pretreatment of healthy volunteers with multiple doses of <e10> drug1 </e10> followed by a single dose of <e21> drug2 </e21> , increased drug2 oral - dose clearance by # - fold , which significantly ( p # ) decreased mean cmax and auc ( 0 - 8 ) .
mechanism	agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of <e11> drug1 </e11> are the following : cisplatin , doxorubicin _ hcl , felbamate , <e20> drug2 </e20> , phenobarbital , phenytoin ( 2 ) , primidone , methsuximide , and theophylline thus , if a patient has been titrated to a stable dosage on drug1 , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for drug1 may be necessary .
mechanism	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma <e10> drug1 </e10> concentrations include : acute alcohol intake , amiodarone , chboramphenicol , chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , h2 - antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , <e20> drug2 </e20> , trazodone
mechanism	multivalent cation - containing products : concurrent administration of a quinolone , including <e10> drug1 </e10> , with multivalent cation - containing products such as <e20> drug2 </e20> or aluminum antacids , sucralfate , videx chewable / buffered tablets or pediatric powder , or products containing calcium , iron , or zinc may substantially decrease the absorption of drug1 , resulting in serum and urine levels considerably lower than desired .
mechanism	<e10> drug1 </e10> may also decrease the absorption of <e20> drug2 </e20> , which can lead to a deficiency .
mechanism	drug1 : <e10> drug1 </e10> may induce the metabolism of <e22> drug2 </e22> causing menstrual changes ;
mechanism	pre - treatment with the cyp3a4 inducer <e10> drug1 </e10> decreased <e20> drug2 </e20> auc by about 2 / 3 .
mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of <e11> drug1 </e11> are the following : acetazolamide , azole _ antifungals , cimetidine , clarithromycin ( 1 ) , dalfopristin , danazol , delavirdine , diltiazem , erythromycin ( 1 ) , fluoxetine , fluvoxamine , grapefruit juice , isoniazid , <e20> drug2 </e20> , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease _ inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate ( 1 ) , verapamil , zileuton .
mechanism	the plasma concentration of <e10> drug1 </e10> may increase when the drug is given concomitantly with hepatic enzyme inhibitors ( e , g , , cimetidine , <e20> drug2 </e20> ) and decrease by concomitant administration of hepatic enzyme inducers ( e , g , , barbiturates , phenytoin ) , and adjustment of the dosage of drug1 may therefore be necessary .
mechanism	although trough citalopram plasma levels were unaffected , given the enzyme - inducing properties of drug1 , the possibility that <e10> drug1 </e10> might increase the clearance of <e20> drug2 </e20> should be considered if the two drugs are coadministered .
mechanism	the results raise the possibility that the ethanolysis reaction may occur in the stomach of people who consume <e10> drug1 </e10> and <e22> drug2 </e22> on a regular basis .
mechanism	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma <e10> drug1 </e10> concentrations include : acute alcohol intake , amiodarone , chboramphenicol , chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , h2 - antagonists , halothane , <e20> drug2 </e20> , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone
mechanism	<e10> drug1 </e10> may decrease serum <e20> drug2 </e20> concentration , especially in patients with renal dysfunction , by increasing the non - renal clearance of drug2 .
mechanism	<e10> drug1 </e10> , naproxen _ sodium and other nsaids have been reported to reduce the tubular secretion of <e20> drug2 </e20> in an animal model , possibly increasing the toxicity of drug2 .
mechanism	antifungals : in vitro and / or in vivo data indicate that fluconazole , itraconazole , and oral <e10> drug1 </e10> markedly inhibit the metabolism of <e20> drug2 </e20> , which can result in an increase in plasma drug2 levels and prolongation of the qt interval on the ecg .
mechanism	substances that are potent inhibitors of cyp3a4 activity ( eg , <e10> drug1 </e10> and itraconazole ) decrease <e20> drug2 </e20> metabolism and increase drug2 plasma concentrations .
mechanism	triazolam : <e10> drug1 </e10> has been reported to decrease the clearance of <e20> drug2 </e20> and , thus , may increase the pharmacologic effect of drug2 .
mechanism	although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 ( eg , calcium _ channel _ blockers , dapsone , disopyramide , <e10> drug1 </e10> , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot _ derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with <e20> drug2 </e20> ;
mechanism	this might be explained by a blockade by <e10> drug1 </e10> of the elimination of <e20> drug2 </e20> by the liver .
mechanism	a drug - drug interaction study with <e10> drug1 </e10> in healthy volunteers has shown a 30 % decrease in <e20> drug2 </e20> trough concentrations .
mechanism	carbamazepine : in healthy subjects receiving the cyp3a4 inducer , <e10> drug1 </e10> , at # mg twice daily for # days and # mg twice daily for # days , systemic exposure ( auc ) to <e20> drug2 </e20> was decreased approximately 72 % .
mechanism	<e10> drug1 </e10> significantly decreases clearance of rifabutin and <e23> drug2 </e23> , and the combination is poorly tolerated .
mechanism	cytochrome p - 450 inducers , such as <e10> drug1 </e10> , carbamazepine and phenobarbital , induce <e20> drug2 </e20> metabolism , causing an approximately 30 % decrease in plasma drug2 levels .
mechanism	theophylline : <e10> drug1 </e10> may inhibit the metabolism of <e20> drug2 </e20> , leading to increased plasma concentrations .
mechanism	total body clearance of <e11> drug1 </e11> was reduced by an average 22 % and 51 % when azathioprine and <e20> drug2 </e20> , respectively , were added to a regimen consisting of cyclosporine , usp ( modified ) and corticosteroids .
mechanism	when used in therapeutic doses , <e10> drug1 </e10> had a modest effect on the pharmacokinetics of atorvastatin , carbamazepine , cetirizine , didanosine , efavirenz , fluconazole , indinavir , midazolam , rifabutin , <e20> drug2 </e20> , theophylline ( intravenous and oral ) , triazolam , trimethoprim / sulfamethoxazole or zidovudine .
mechanism	metformin : in healthy subjects given single # mg doses of <e10> drug1 </e10> and <e20> drug2 </e20> , plasma drug2 mean cmax and auc increased by an average of 34 % and 24 % , respectively , and drug2 mean renal clearance decreased by 14 % .
mechanism	the plasma concentration of <e10> drug1 </e10> may increase when the drug is given concomitantly with hepatic enzyme inhibitors ( e , g , , <e20> drug2 </e20> , fluoxetine ) and decrease by concomitant administration of hepatic enzyme inducers ( e , g , , barbiturates , phenytoin ) , and adjustment of the dosage of drug1 may therefore be necessary .
mechanism	leucovorin : the concentration of <e10> drug1 </e10> is increased and its toxicity may be enhanced by <e20> drug2 </e20> .
mechanism	cyclosporine : modest increases in mean trough <e10> drug1 </e10> concentrations were observed following initiation of <e20> drug2 </e20> treatment in # renal transplant patients suffering from chronic vascular rejection .
mechanism	monoamine _ oxidase _ inhibitors : coadministration of <e10> drug1 </e10> resulted in a 27 % decrease in <e20> drug2 </e20> clearance and an increase in cmax of approximately 6 % .
mechanism	valproate : the addition of drug2 to patients taking drug1 chronically had no effect on drug2 pharmacokinetics , but <e10> drug1 </e10> significantly decreased <e20> drug2 </e20> binding in vitro from # to # % , which resulted in an increase of approximately 40 % in the free drug2 concentration .
mechanism	<e10> drug1 </e10> markedly increases the metabolic clearance of <e20> drug2 </e20> , and coadministration is contraindicated .
mechanism	agents with increased levels in the presence of carbamazepine : <e11> drug1 </e11> increases the plasma levels of the following agents : clomipramine _ hcl , <e20> drug2 </e20> ( 6 ) , and primidone thus , if a patient has been titrated to a stable dosage on one of the agents in this category , and then begins a course of the treatment with drug1 , it is reasonable to expect that a dose decrease for the concomitant agent may be necessary .
mechanism	when used in therapeutic doses , <e10> drug1 </e10> had a modest effect on the pharmacokinetics of atorvastatin , carbamazepine , cetirizine , didanosine , efavirenz , fluconazole , indinavir , midazolam , rifabutin , sildenafil , theophylline ( intravenous and oral ) , <e20> drug2 </e20> , trimethoprim / sulfamethoxazole or zidovudine .
mechanism	erythromycin : in healthy individuals , plasma concentrations of drug1 increased approximately 40 % with coadministration of <e10> drug1 </e10> and <e20> drug2 </e20> , a known inhibitor of cytochrome p450 3a4 .
mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of <e11> drug1 </e11> are the following : acetazolamide , azole _ antifungals , cimetidine , clarithromycin ( 1 ) , dalfopristin , danazol , delavirdine , diltiazem , erythromycin ( 1 ) , fluoxetine , fluvoxamine , grapefruit juice , <e20> drug2 </e20> , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease _ inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate ( 1 ) , verapamil , zileuton .
mechanism	anticonvulsants ( <e10> drug1 </e10> , felbamate , phenobarbital , phenytoin , topiramate ) : increase the metabolism of ethinyl _ estradiol and / or some <e22> drug2 </e22> , leading to possible decrease in contraceptive effectiveness .
mechanism	quinolone _ antibiotic s : videx should be administered at least # hours after or # hours before dosing with drug1 because plasma concentrations of <e10> drug1 </e10> are decreased when administered with antacids containing magnesium , calcium , or <e20> drug2 </e20> .
mechanism	probenecid or cimetidine : concomitant administration of probenecid or <e10> drug1 </e10> decreases the elimination of <e20> drug2 </e20> , most likely by inhibition of renal tubular secretion of drug2 .
mechanism	simvastatin and other statins : co - administration of <e10> drug1 </e10> decreased the plasma concentrations of <e20> drug2 </e20> ( a cyp3a4 substrate ) , and its active - hydroxy acid metabolite , by approximately 50 % .
mechanism	binding to serum proteins : the following agents may either inhibit <e10> drug1 </e10> binding to serum proteins or alter the concentrations of serum binding proteins : androgens and related anabolic _ hormones , asparaginase , clofibrate , estrogens and estrogen - containing _ compounds , 5 - fluorouracil , furosemide , glucocorticoids , meclofenamic _ acid , mefenamic _ acid , methadone , perphenazine , phenylbutazone , phenytoin , <e22> drug2 </e22> , tamoxifen .
mechanism	coadministration of <e10> drug1 </e10> decreased the maximum plasma concentration of <e20> drug2 </e20> by 6 % , decreased clearance by 38 % , and increased half - life by 58 % .
mechanism	<e10> drug1 </e10> , astemizole and cisapride are all metabolized by the cytochrome p450iiia4 isozyme , and it has been demonstrated that <e20> drug2 </e20> , a potent inhibitor of iiia4 , blocks the metabolism of these drugs , resulting in increased plasma concentrations of parent drug .
mechanism	the following are examples of drugs known to inhibit the metabolism of other related <e12> drug1 </e12> , presumably through inhibition of cyp3a : nefazodone , fluvoxamine , <e20> drug2 </e20> , diltiazem , isoniazide , and some macrolide _ antibiotics .
mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of <e11> drug1 </e11> are the following : acetazolamide , azole _ antifungals , cimetidine , clarithromycin ( 1 ) , dalfopristin , danazol , delavirdine , diltiazem , erythromycin ( 1 ) , fluoxetine , <e20> drug2 </e20> , grapefruit juice , isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease _ inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate ( 1 ) , verapamil , zileuton .
mechanism	plasma exposure ( auc ) to <e10> drug1 </e10> was increased 62 % when coadministered with fluconazole and 38 % when coadministered with <e20> drug2 </e20> .
mechanism	there was a small decrease in the clearance of <e10> drug1 </e10> caused by a 400 - mg dose of <e20> drug2 </e20> ;
mechanism	effects of other antiepilepsy drugs ( aeds ) on gabitril : carbamazepine : population pharmacokinetic analyses indicate that <e10> drug1 </e10> clearance is 60 % greater in patients taking <e20> drug2 </e20> with or without other enzyme - inducing aeds .
mechanism	mao _ inhibitors maoi _ antidepressants , as well as a metabolite of <e10> drug1 </e10> , slow <e20> drug2 </e20> metabolism .
mechanism	phenytoin : <e10> drug1 </e10> may increase serum levels of <e20> drug2 </e20> .
mechanism	increasing the drug1 dose to # mg every # hours does not compensate for the increased <e10> drug1 </e10> metabolism due to <e21> drug2 </e21> .
mechanism	multivalent cation - containing products : concurrent administration of a <e12> drug1 </e12> , including ciprofloxacin , with multivalent cation - containing products such as <e20> drug2 </e20> or aluminum antacids , sucralfate , videx chewable / buffered tablets or pediatric powder , or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .
mechanism	warfarin , digoxin , salicylate , and heparin the in vitro binding of <e10> drug1 </e10> to plasma proteins is only slightly reduced by <e20> drug2 </e20> ( # % control vs # % ) when ketorolac plasma concentrations reach # to10 m g / ml .
mechanism	inhibitors or substrates of cyp2d6 ( i , e , , quinidine , selective _ serotonin _ reuptake _ inhibitors [ <e12> drug1 </e12> ] ) may increase the plasma concentration of <e20> drug2 </e20> when administered concomitantly .
mechanism	although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 ( eg , calcium _ channel _ blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , <e10> drug1 </e10> , cyclosporine , ergot _ derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with <e20> drug2 </e20> ;
mechanism	although no clinical studies have been conducted , it is likely that the metabolism of <e10> drug1 </e10> may be affected by the known cyp3a4 inducers ( such as phenytoin , phenobarbital , <e20> drug2 </e20> ) , cyp3a4 inhibitors ( azole antimycotics e , g , , ketoconazole ;
mechanism	binding to serum proteins : the following agents may either inhibit <e10> drug1 </e10> binding to serum proteins or alter the concentrations of serum binding proteins : androgens and related anabolic _ hormones , asparaginase , clofibrate , estrogens and estrogen - containing _ compounds , 5 - fluorouracil , furosemide , glucocorticoids , meclofenamic _ acid , mefenamic _ acid , methadone , <e20> drug2 </e20> , phenylbutazone , phenytoin , salicylates , tamoxifen .
mechanism	some quinolones , including <e10> drug1 </e10> , have also been shown to interfere with the metabolism of <e20> drug2 </e20> .
mechanism	drugs that induce hepatic enzymes such as phenobarbital , <e10> drug1 </e10> and rifampin may increase the clearance of <e22> drug2 </e22> and may require increases in corticosteroid dose to achieve the desired response .
mechanism	mercaptopurine / azathioprine : <e10> drug1 </e10> inhibits the enzymatic oxidation of <e20> drug2 </e20> and azathioprine to 6 - thiouric _ acid .
mechanism	( 1968 , 1970 ) , the higher serum concentrations of penicillins and <e10> drug1 </e10> reached after administration of <e20> drug2 </e20> are due not only to slower renal elimination but also to an altered distribution in the body .
mechanism	lithium : in a study conducted in healthy subjects , mean steady - state drug1 plasma levels increased approximately 17 % in subjects receiving <e10> drug1 </e10> # mg bid with <e21> drug2 </e21> # mg bid as compared to subjects receiving drug1 alone .
mechanism	phenytoin : <e12> drug1 </e12> may delay intestinal absorption of <e20> drug2 </e20> ;
mechanism	lithium : <e10> drug1 </e10> # mg bid for # days produced significant decreases in <e20> drug2 </e20> serum clearance ( 25 % ) and renal clearance ( 30 % ) with a 34 % higher serum exposure compared to drug2 alone .
mechanism	antibiotics : in vitro and / or in vivo data show that <e10> drug1 </e10> , erythromycin , and troleandomycin markedly inhibit the metabolism of <e20> drug2 </e20> , which can result in an increase in plasma drug2 levels and prolongation of the qt interval on the ecg .
mechanism	warfarin : quinolones , including <e10> drug1 </e10> , decrease the clearance of <e20> drug2 </e20> , the less active isomer of racemic warfarin .
mechanism	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma <e10> drug1 </e10> concentrations include : acute alcohol intake , amiodarone , chboramphenicol , chlordiazepoxide , cimetidine , diazepam , dicumarol , <e20> drug2 </e20> , estrogens , ethosuximide , fluoxetine , h2 - antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone
mechanism	salicylic _ acid : combination <e12> drug1 </e12> may increase the clearance of <e20> drug2 </e20> .
mechanism	specific effects of drug1 on other antiepileptic _ drugs phenytoin : <e11> drug1 </e11> causes an increase in steady - state <e20> drug2 </e20> plasma concentrations .
mechanism	on the basis of the metabolism of drug2 by cytochrome p450 3a4 , <e10> drug1 </e10> , itraconazole , erythromycin , gemfibrozil , grapefruit juice , and other inhibitors of cytochrome p450 3a4 would be expected to lead to an increase in plasma <e20> drug2 </e20> concentrations .
mechanism	methotrexate : ketoprofen , like other <e12> drug1 </e12> , may cause changes in the elimination of <e20> drug2 </e20> leading to elevated serum levels of the drug and increased toxicity .
mechanism	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma <e10> drug1 </e10> concentrations include : acute alcohol intake , amiodarone , chboramphenicol , chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , <e22> drug2 </e22> , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone
mechanism	tricyclic _ antidepressants ( amitriptyline , imipramine , <e10> drug1 </e10> ) : metabolism may be inhibited by <e22> drug2 </e22> , increasing plasma levels of antidepressant ;
mechanism	ingestion of <e10> drug1 </e10> may increase serum concentrations of digoxin and <e20> drug2 </e20> and increase cyclosporine s nephrotoxicity .
mechanism	interactions for vitamin _ d _ analogues ( vitamin _ d2 , vitamin _ d3 , calcitriol , and calcidiol ) : drug1 : <e10> drug1 </e10> has been reported to reduce intestinal absorption of <e22> drug2 </e22> ;
mechanism	a # ( 17 ) % decrease in the steady - state auc of drug2 was observed when <e11> drug1 </e11> was administered # hours prior to <e20> drug2 </e20> , but not when the two drugs were administered simultaneously ( n = 12 ) .
mechanism	the following are examples of drugs known to inhibit the metabolism of other related <e12> drug1 </e12> , presumably through inhibition of cyp3a : nefazodone , fluvoxamine , cimetidine , <e20> drug2 </e20> , isoniazide , and some macrolide _ antibiotics .
mechanism	urinary acidifying agents these agents ( ammonium _ chloride , <e10> drug1 </e10> , etc , ) increase the concentration of the ionized species of the <e20> drug2 </e20> molecule , thereby increasing urinary excretion .
mechanism	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma <e10> drug1 </e10> concentrations include : acute alcohol intake , amiodarone , chboramphenicol , chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , <e20> drug2 </e20> , fluoxetine , h2 - antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone
mechanism	conversely , decreases in plasma levels of the <e12> drug1 </e12> have been reported upon discontinuation of <e20> drug2 </e20> which may result in the loss of the therapeutic efficacy of the tricyclic _ antidepressant 6 .
mechanism	uricosuric _ agents : since the excretion of drug2 is similar to that of urate , <e12> drug1 </e12> , which increase the excretion of urate , are also likely to increase the excretion of <e20> drug2 </e20> and thus lower the degree of inhibition of xanthine oxidase .
mechanism	the gastrointestinal absorption of <e10> drug1 </e10> and ranitidine is accelerated when they are coadministered with <e20> drug2 </e20> .
mechanism	mercaptopurine / azathioprine : <e10> drug1 </e10> inhibits the enzymatic oxidation of mercaptopurine and <e20> drug2 </e20> to 6 - thiouric _ acid .
mechanism	population pharmacokinetic studies showed higher concentrations of <e10> drug1 </e10> among patients concurrently treated with <e20> drug2 </e20> , an inhibitor of c , p , a , .
mechanism	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma <e10> drug1 </e10> concentrations include : acute alcohol intake , amiodarone , chboramphenicol , chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , h2 - antagonists , halothane , isoniazid , <e20> drug2 </e20> , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone
mechanism	<e10> drug1 </e10> significantly decreases clearance of <e20> drug2 </e20> and 25 - o - desacetyl drug2 , and the combination is poorly tolerated .
mechanism	ketoconazole - combined administration of racemic <e10> drug1 </e10> ( 40 mg ) and <e20> drug2 </e20> ( 200 mg ) decreased the cmax and auc of drug2 by 21 % and 10 % , respectively , and did not significantly affect the pharmacokinetics of drug1 .
mechanism	limited clinical experience indicates that requirements for <e12> drug1 </e12> are reduced by # to 50 % for the first sixty ( 60 ) minutes following <e21> drug2 </e21> induction the concomitant use of erythromycin with drug2 can significantly inhibit drug2 clearance and may increase the risk of prolonged or delayed respiratory depression .
mechanism	because drug2 has not been shown to produce any additional effect beyond that obtained with drug1 alone and because <e11> drug1 </e11> increases the rate of excretion of <e21> drug2 </e21> , the concomitant use of drug2 and salicylates is not recommended .
mechanism	inhibitors of cyp3a4 ( eg , ketoconazole ) or cyp2d6 ( eg , quinidine , <e10> drug1 </e10> , or paroxetine ) can inhibit <e20> drug2 </e20> elimination and cause increased blood levels .
mechanism	binding to serum proteins : the following agents may either inhibit <e10> drug1 </e10> binding to serum proteins or alter the concentrations of serum binding proteins : androgens and related <e22> drug2 </e22> , asparaginase , clofibrate , estrogens and estrogen - containing _ compounds , 5 - fluorouracil , furosemide , glucocorticoids , meclofenamic _ acid , mefenamic _ acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen .
mechanism	previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and <e10> drug1 </e10> when administered concomitantly with an intravenous <e22> drug2 </e22> such as morphine .
mechanism	the coadministration of <e11> drug1 </e11> decreases the biologic half - life of <e20> drug2 </e20> because of an increase in metabolic clearance that results in a greater amount of hydroxylated _ drug2 in the urine .
mechanism	levothyroxine _ sodium absorption : the following agents may bind and decrease absorption of <e10> drug1 </e10> from the gastrointestinal tract : aluminum _ hydoxide , cholestyramine resin , <e20> drug2 </e20> , ferrous _ sulfate , sodium _ polystyrene _ sulfonate , soybean flour ( e , g , , infant formula ) , sucralfate .
mechanism	hepatic enzyme inducers , inhibitors and substrates : drugs which induce cytochrome p450 3a4 ( cyp 3a4 ) enzyme activity ( e , g , , <e12> drug1 </e12> , phenytoin , carbamazepine , rifampin ) may enhance the metabolism of <e22> drug2 </e22> and require that the dosage of the corticosteroid be increased .
mechanism	although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 ( eg , calcium _ channel _ blockers , dapsone , <e10> drug1 </e10> , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot _ derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with <e20> drug2 </e20> ;
mechanism	mao _ inhibitors : maoi _ antidepressants , as well as a metabolite of <e10> drug1 </e10> , slow <e20> drug2 </e20> metabolism .
mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of <e11> drug1 </e11> are the following : acetazolamide , azole _ antifungals , cimetidine , clarithromycin ( 1 ) , dalfopristin , danazol , delavirdine , diltiazem , erythromycin ( 1 ) , fluoxetine , fluvoxamine , grapefruit juice , isoniazid , itraconazole , ketoconazole , loratadine , <e20> drug2 </e20> , niacinamide , nicotinamide , protease _ inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate ( 1 ) , verapamil , zileuton .
mechanism	cimetidine , <e10> drug1 </e10> , and erythromycin may increase plasma levels of <e20> drug2 </e20> , potentially resulting in adverse effects .
mechanism	the plasma concentration of <e10> drug1 </e10> may increase when the drug is given concomitantly with hepatic enzyme inhibitors ( e , g , , cimetidine , fluoxetine ) and decrease by concomitant administration of hepatic enzyme inducers ( e , g , , <e22> drug2 </e22> , phenytoin ) , and adjustment of the dosage of drug1 may therefore be necessary .
mechanism	cimetidine : in the presence of <e10> drug1 </e10> at # mg qid ( n = 12 ) the mean apparent oral clearance of <e20> drug2 </e20> fell by 14 % and creatinine clearance fell by 10 % .
mechanism	human pharmacokinetic data indicate that oral <e10> drug1 </e10> markedly inhibits the metabolism of <e20> drug2 </e20> , resulting in a mean eight - fold increase in auc of drug2 .
mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of <e11> drug1 </e11> are the following : acetazolamide , <e22> drug2 </e22> , cimetidine , clarithromycin ( 1 ) , dalfopristin , danazol , delavirdine , diltiazem , erythromycin ( 1 ) , fluoxetine , fluvoxamine , grapefruit juice , isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease _ inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate ( 1 ) , verapamil , zileuton .
mechanism	cimetidine - in subjects who had received # days of # mg / day racemic <e10> drug1 </e10> , combined administration of # mg / day <e20> drug2 </e20> for # days resulted in an increase in drug1 auc and cmax of 43 % and 39 % , respectively .
mechanism	substances that are potent inhibitors of cyp3a4 activity ( eg , ketoconazole and <e10> drug1 </e10> ) decrease drug2 metabolism and increase <e20> drug2 </e20> plasma concentrations .
mechanism	iron _ supplements and foods fortified with iron concomitant administration of <e10> drug1 </e10> with a therapeutic drug2 _ supplement containing # mg of elemental <e20> drug2 </e20> ( as feso4 ) or vitamins supplemented with # mg of elemental drug2 reduced extent of absorption by 80 % and 31 % , respectively .
mechanism	antacids and sucralfate : sucralfate and antacids containing <e10> drug1 </e10> or aluminum , as well as formulations containing divalent and trivalent cations such as videx ( didanosine ) , chewable / buffered tablets or the pediatric powder for oral solution can form chelation complexes with <e20> drug2 </e20> and interfere with its bioavailability .
mechanism	drugs which induce cyp3a4 activity ( eg , phenobarbital , <e10> drug1 </e10> , rifabutin ) would be expected to increase the clearance of <e20> drug2 </e20> resulting in lowered plasma concentrations .
mechanism	inhibitors of cyp1a2 : concomitant use of <e10> drug1 </e10> with <e20> drug2 </e20> , an inhibitor of cyp1a2 , results in approximately a 6 - fold increase in auc and about a # - fold increase in cmax of drug1 .
mechanism	substances that are potent inhibitors of cyp3a4 activity ( eg , <e10> drug1 </e10> and itraconazole ) decrease drug2 metabolism and increase <e20> drug2 </e20> plasma concentrations .
mechanism	drug1 : <e10> drug1 </e10> may inhibit both synthetic and catabolic enzymes of <e22> drug2 </e22> .
mechanism	coadministration of oral <e12> drug1 </e12> increased the maximum plasma concentration of <e20> drug2 </e20> by 18 % , decreased clearance by 22 % , and increased half - life by 29 % .
mechanism	total body clearance of <e11> drug1 </e11> was reduced by an average 22 % and 51 % when <e20> drug2 </e20> and mycophenolate _ mofetil , respectively , were added to a regimen consisting of cyclosporine , usp ( modified ) and corticosteroids .
mechanism	binding to serum proteins : the following agents may either inhibit <e10> drug1 </e10> binding to serum proteins or alter the concentrations of serum binding proteins : androgens and related anabolic _ hormones , <e20> drug2 </e20> , clofibrate , estrogens and estrogen - containing _ compounds , 5 - fluorouracil , furosemide , glucocorticoids , meclofenamic _ acid , mefenamic _ acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen .
mechanism	the elimination half life of <e10> drug1 </e10> and triazolam also increased ( # # fold ) during coadministration with <e20> drug2 </e20> .
mechanism	in addition , higher - than expected steady - state serum concentrations of <e12> drug1 </e12> have been observed when therapy is initiated in patients already taking <e20> drug2 </e20> .
mechanism	antacids : in a clinical pharmacology study , coadministration of an antacid ( aluminum _ hydroxide , magnesium _ hydroxide , and simethicone ) with drug2 reduced serum levels and urinary excretion of drug2 at as compared with drug2 administered alone , suggesting that <e12> drug1 </e12> may impair absorption of <e20> drug2 </e20> .
mechanism	protein binding in vitro , <e10> drug1 </e10> interferes minimally or not at all with the protein binding of salicylic _ acid ( 20 % decrease in binding ) , <e20> drug2 </e20> , prednisolone ( 10 % decrease in binding ) , or warfarin .
mechanism	tolbutamide : drug2 , when given as # mg on day # and # mg / day on days # and 3 , decreased the auc of drug1 ( a cyp2c9 substrate ) by 23 % on day 4 , 28 % on day 8 , and 15 % on day 15 , when a single dose of <e10> drug1 </e10> # mg was admini , stered orally prior to the administration of the 3 - day regimen of <e20> drug2 </e20> and on days 4 , 8 , and 15 .
mechanism	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma <e10> drug1 </e10> concentrations include : acute alcohol intake , amiodarone , chboramphenicol , chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , h2 - antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , <e20> drug2 </e20>
mechanism	drugs that induce hepatic enzymes such as <e10> drug1 </e10> , phenytoin and rifampin may increase the clearance of <e22> drug2 </e22> and may require increases in corticosteroid dose to achieve the desired response .
mechanism	the auc of <e10> drug1 </e10> was increased # - fold by coadministration of <e20> drug2 </e20> , a potent inhibitor of cyp3a4 , # mg daily for # days .
mechanism	carbamazepine : <e10> drug1 </e10> is known to slow the metabolism of <e20> drug2 </e20> and increase its serum levels carbamazepine levels should be determined prior to concurrent administration with isoniazid , signs and symptoms of drug2 toxicity should be monitored closely , and appropriate dosage adjustment of the anticonvulsant should be made .
mechanism	alkalinizing agents : gastrointestinal alkalinizing agents ( <e10> drug1 </e10> , etc , ) increase absorption of <e20> drug2 </e20> .
mechanism	apparent oral clearance and volume of distribution of drug1 decreased with 38 % and 45 % , respectively , when <e10> drug1 </e10> was given with <e20> drug2 </e20> .
mechanism	allopurinol : the auc of didanosine was increased about 4 - fold when <e10> drug1 </e10> at # mg / day was coadministered with a single 200 - mg dose of <e21> drug2 </e21> to two patients with renal impairment ( clcr = 15 and # ml / min ) .
mechanism	caffeine theobromine <e10> drug1 </e10> , like other quinolones , may inhibit the metabolism of caffeine and <e20> drug2 </e20> .
mechanism	presumably , <e10> drug1 </e10> acts as a stimulator of <e22> drug2 </e22> metabolism and has been reported to cause decreased serum levels of the drug2 _ anticoagulants and increased prothrombin - proconvertin concentrations .
mechanism	binding to serum proteins : the following agents may either inhibit <e10> drug1 </e10> binding to serum proteins or alter the concentrations of serum binding proteins : androgens and related anabolic _ hormones , asparaginase , clofibrate , estrogens and estrogen - containing _ compounds , 5 - fluorouracil , furosemide , glucocorticoids , <e20> drug2 </e20> , mefenamic _ acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen .
mechanism	the mean clearances of <e10> drug1 </e10> were 16 % and 15 % lower in patients on <e22> drug2 </e22> and inhibitors of tubular organic cation transport , respectively .
mechanism	ampicillin : in a study of healthy volunteers , <e10> drug1 </e10> significantly reduced the bioavailability of <e20> drug2 </e20> .
mechanism	benzodiazepines : combination <e12> drug1 </e12> may decrease the clearance of some benzodiazepines ( alprazolam , chlordiazepoxide , diazepam ) and increase the clearance of others ( lorazepam , oxazepam , <e20> drug2 </e20> ) .
mechanism	agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of <e11> drug1 </e11> are the following : cisplatin , doxorubicin _ hcl , <e20> drug2 </e20> , rifampin , phenobarbital , phenytoin ( 2 ) , primidone , methsuximide , and theophylline thus , if a patient has been titrated to a stable dosage on drug1 , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for drug1 may be necessary .
mechanism	when used in therapeutic doses , <e10> drug1 </e10> had a modest effect on the pharmacokinetics of atorvastatin , carbamazepine , cetirizine , didanosine , efavirenz , fluconazole , indinavir , <e20> drug2 </e20> , rifabutin , sildenafil , theophylline ( intravenous and oral ) , triazolam , trimethoprim / sulfamethoxazole or zidovudine .
mechanism	when used in therapeutic doses , <e10> drug1 </e10> had a modest effect on the pharmacokinetics of atorvastatin , carbamazepine , cetirizine , didanosine , efavirenz , <e20> drug2 </e20> , indinavir , midazolam , rifabutin , sildenafil , theophylline ( intravenous and oral ) , triazolam , trimethoprim / sulfamethoxazole or zidovudine .
mechanism	agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of <e11> drug1 </e11> are the following : cisplatin , doxorubicin _ hcl , felbamate , rifampin , phenobarbital , <e20> drug2 </e20> ( 2 ) , primidone , methsuximide , and theophylline thus , if a patient has been titrated to a stable dosage on drug1 , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for drug1 may be necessary .
mechanism	drug1 : <e10> drug1 </e10> is known to interact with the metabolism or renal tubular excretion of many drugs ( e , g , , acetaminophen , acyclovir , angiotensin - converting _ enzyme _ inhibitors , aminosalicylic _ acid , barbiturates , benzodiazepines , bumetanide , clofibrate , methotrexate , famotidine , <e20> drug2 </e20> , nonsteroidal _ anti - inflammatory agents , theophylline , and zidovudine ) .
mechanism	effect of drug2 in pediatric patients there was about a 22 % increase of apparent total body clearance of <e10> drug1 </e10> when it was co - administered with enzyme - inducing <e22> drug2 </e22> .
mechanism	binding to serum proteins : the following agents may either inhibit <e10> drug1 </e10> binding to serum proteins or alter the concentrations of serum binding proteins : androgens and related anabolic _ hormones , asparaginase , clofibrate , estrogens and <e22> drug2 </e22> , 5 - fluorouracil , furosemide , glucocorticoids , meclofenamic _ acid , mefenamic _ acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen .
mechanism	anticonvulsants : in a pharmacokinetic study , maximum plasma concentrations of <e10> drug1 </e10> were considerably lower in epileptic patients on long - term anticonvulsant therapy ( eg , <e20> drug2 </e20> , carbamazepine , or phenobarbital ) than in healthy volunteers .
mechanism	warfarin : co - administration of <e10> drug1 </e10> # mg b , i , d , for # days decreased the plasma concentrations of both s - warfarin ( a cyp2c9 substrate ) and <e20> drug2 </e20> ( a cyp3a4 substrate ) by # and 38 % , respectively .
mechanism	it is known that cyp1a2 is inhibited by several medicinal products , including <e10> drug1 </e10> , and such medicinal products could theoretically adversely influence the clearance of <e20> drug2 </e20> .
mechanism	mao _ inhibitors : <e12> drug1 </e12> , as well as a metabolite of furazolidone , slow <e20> drug2 </e20> metabolism .
mechanism	co - administration of <e10> drug1 </e10> decreased the plasma concentrations of <e20> drug2 </e20> ( a cyp3a4 substrate ) by approximately 50 % .
mechanism	binding to serum proteins : the following agents may either inhibit <e10> drug1 </e10> binding to serum proteins or alter the concentrations of serum binding proteins : androgens and related anabolic _ hormones , asparaginase , clofibrate , estrogens and estrogen - containing _ compounds , 5 - fluorouracil , furosemide , <e22> drug2 </e22> , meclofenamic _ acid , mefenamic _ acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen .
mechanism	a # to 45 % increase in auc and cmax of <e10> drug1 </e10> was observed with concomitant administration of <e20> drug2 </e20> twice daily .
mechanism	although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 ( eg , calcium _ channel _ blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot _ derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and <e10> drug1 </e10> ) may have elevated plasma concentrations when coadministered with <e20> drug2 </e20> ;
mechanism	however , # mg of <e10> drug1 </e10> q12h for # days increased the drug2 c max by 23 % and <e20> drug2 </e20> auc by 16 % .
mechanism	anticonvulsants ( carbamazepine , felbamate , phenobarbital , <e10> drug1 </e10> , topiramate ) : increase the metabolism of <e20> drug2 </e20> and / or some progestins , leading to possible decrease in contraceptive effectiveness .
mechanism	ketoconazole : co - administration of <e10> drug1 </e10> # mg b , i , d , and <e20> drug2 </e20> , a potent cyp3a4 inhibitor , increased the plasma concentrations of drug1 by approximately 2 - fold .
mechanism	cyclosporine : combination <e12> drug1 </e12> may inhibit the metabolism of <e20> drug2 </e20> , leading to increased plasma concentrations ;
mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of <e11> drug1 </e11> are the following : acetazolamide , azole _ antifungals , cimetidine , clarithromycin ( 1 ) , dalfopristin , <e20> drug2 </e20> , delavirdine , diltiazem , erythromycin ( 1 ) , fluoxetine , fluvoxamine , grapefruit juice , isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease _ inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate ( 1 ) , verapamil , zileuton .
mechanism	agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of <e11> drug1 </e11> are the following : cisplatin , doxorubicin _ hcl , felbamate , rifampin , phenobarbital , phenytoin ( 2 ) , primidone , <e20> drug2 </e20> , and theophylline thus , if a patient has been titrated to a stable dosage on drug1 , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for drug1 may be necessary .
mechanism	terfenadine , <e10> drug1 </e10> and cisapride are all metabolized by the cytochrome p450iiia4 isozyme , and it has been demonstrated that <e20> drug2 </e20> , a potent inhibitor of iiia4 , blocks the metabolism of these drugs , resulting in increased plasma concentrations of parent drug .
mechanism	multivalent cation - containing products : concurrent administration of a <e12> drug1 </e12> , including ciprofloxacin , with multivalent cation - containing products such as magnesium or aluminum <e22> drug2 </e22> , sucralfate , videx chewable / buffered tablets or pediatric powder , or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .
mechanism	naproxen , <e10> drug1 </e10> and other nsaids have been reported to reduce the tubular secretion of <e20> drug2 </e20> in an animal model , possibly increasing the toxicity of drug2 .
mechanism	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma <e10> drug1 </e10> concentrations include : acute alcohol intake , amiodarone , chboramphenicol , chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , h2 - antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , <e22> drug2 </e22> , sulfonamides , tolbutamide , trazodone
mechanism	when used in therapeutic doses , <e10> drug1 </e10> had a modest effect on the pharmacokinetics of atorvastatin , carbamazepine , cetirizine , didanosine , efavirenz , fluconazole , indinavir , midazolam , rifabutin , sildenafil , theophylline ( intravenous and oral ) , triazolam , trimethoprim / <e20> drug2 </e20> or zidovudine .
mechanism	probenecid : as with other <e12> drug1 </e12> , renal excretion of loracarbef is inhibited by <e20> drug2 </e20> and resulted in an approximate 80 % increase in the auc for loracarbef .
mechanism	cimetidine : a study in # healthy volunteers has shown a significant increase in peak drug2 plasma levels ( 80 % ) and area - under - the - curve ( 74 % ) after a # week course of <e10> drug1 </e10> at # mg per day and <e20> drug2 </e20> at # mg per day .
mechanism	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma <e10> drug1 </e10> concentrations include : acute <e20> drug2 </e20> intake , amiodarone , chboramphenicol , chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , h2 - antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone
mechanism	furosemide : when <e10> drug1 </e10> was co - administered with <e20> drug2 </e20> , the auc and cmax of drug2 were reduced by about 30 % and 50 % , respectively .
mechanism	protease _ inhibitors : in vitro data indicate that indinavir and <e10> drug1 </e10> markedly inhibit the metabolism of <e20> drug2 </e20> which can result in an increase in plasma drug2 levels and prolongation of the qt interval on the ecg .
mechanism	the gastrointestinal absorption of cimetidine and <e10> drug1 </e10> is accelerated when they are coadministered with <e20> drug2 </e20> .
mechanism	- cholestyramine and colestipol resins : <e10> drug1 </e10> and colestipol resins have the potential of binding <e22> drug2 </e22> and reducing diuretic absorption from the gastrointestinal tract
mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of <e11> drug1 </e11> are the following : acetazolamide , azole _ antifungals , cimetidine , clarithromycin ( 1 ) , dalfopristin , danazol , delavirdine , diltiazem , erythromycin ( 1 ) , fluoxetine , fluvoxamine , grapefruit juice , isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease _ inhibitors , propoxyphene , <e20> drug2 </e20> , quinupristin , troleandomycin , valproate ( 1 ) , verapamil , zileuton .
mechanism	drugs which inhibit cyp 3a4 ( e , g , , ketoconazole , <e12> drug1 </e12> such as erythromycin ) have the potential to result in increased plasma concentrations of <e22> drug2 </e22> .
mechanism	antacids or h _ 2 _ receptor _ antagonists : when <e10> drug1 </e10> is administered immediately following <e22> drug2 </e22> or h _ 2 _ - receptor _ antagonists , the absorption of drug1 is slightly enhanced .
mechanism	this report describes two cases in which <e10> drug1 </e10> clearance accelerated markedly with concomitant <e20> drug2 </e20> administration .
mechanism	plasma levels of several closely related tricyclic _ antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors ( e , g , , cimetidine , fluoxetine ) and decreased by the concomitant administration of hepatic enzyme inducers ( e , g , , <e12> drug1 </e12> , phenytoin ) , and such an effect may be anticipated with <e20> drug2 </e20> as well .
mechanism	phenobarbital ( primidone ) : population pharmacokinetic analyses indicate that <e10> drug1 </e10> clearance is 60 % greater in patients taking <e20> drug2 </e20> ( primidone ) with or without other enzyme - inducing aeds .
mechanism	however , other published reports describe modest elevations ( less than two - fold ) of drug1 and metabolite concentrations when <e10> drug1 </e10> was taken with <e20> drug2 </e20> , fluoxetine , and sertraline .
mechanism	the cmax of <e10> drug1 </e10> was 13 % higher when it was coadministered with <e20> drug2 </e20> ;
mechanism	hepatic enzyme inducers , inhibitors and substrates : drugs which induce cytochrome p450 3a4 ( cyp 3a4 ) enzyme activity ( e , g , , barbiturates , phenytoin , carbamazepine , <e10> drug1 </e10> ) may enhance the metabolism of <e22> drug2 </e22> and require that the dosage of the corticosteroid be increased .
mechanism	multivalent cation - containing products : concurrent administration of a <e12> drug1 </e12> , including ciprofloxacin , with multivalent cation - containing products such as magnesium or aluminum antacids , sucralfate , videx chewable / buffered tablets or pediatric powder , or products containing calcium , <e20> drug2 </e20> , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .
mechanism	probenecid : as with other b - lactam _ antibiotics , <e10> drug1 </e10> inhibits the renal excretion of <e20> drug2 </e20> , resulting in an approximate doubling in a , c , a 54 % increase in peak drug2 plasma levels , and a 50 % prolongation in the apparent elimination half - life .
mechanism	concurrent use of <e10> drug1 </e10> increases the metabolic clearance of <e21> drug2 </e21> , resulting in a shortened elimination half - life of drug2 .
mechanism	fluconazole : concomitant administration of <e10> drug1 </e10> at # mg qd resulted in a two - fold increase in <e20> drug2 </e20> plasma concentration .
mechanism	increasing the <e10> drug1 </e10> dose to # mg / day increased the steadystate <e20> drug2 </e20> cmin to # 25 micrograms / ml .
mechanism	binding to serum proteins : the following agents may either inhibit <e10> drug1 </e10> binding to serum proteins or alter the concentrations of serum binding proteins : androgens and related anabolic _ hormones , asparaginase , clofibrate , estrogens and estrogen - containing _ compounds , 5 - fluorouracil , <e20> drug2 </e20> , glucocorticoids , meclofenamic _ acid , mefenamic _ acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen .
mechanism	plasma levels of several closely related <e12> drug1 </e12> have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors ( e , g , , cimetidine , fluoxetine ) and decreased by the concomitant administration of hepatic enzyme inducers ( e , g , , barbiturates , <e20> drug2 </e20> ) , and such an effect may be anticipated with cmi as well .
mechanism	antidepressants : in vitro data indicate that <e10> drug1 </e10> inhibits the metabolism of <e20> drug2 </e20> , which can result in an increase in plasma drug2 levels and prolongation of the qt interval on the ecg .
mechanism	geocillin ( <e10> drug1 </e10> ) blood levels may be increased and prolonged by concurrent administration of <e20> drug2 </e20> .
mechanism	drug interactions with antacids administration of # mg of <e10> drug1 </e10> ( 2 x # mg capsule ) within # minutes of an <e20> drug2 </e20> and magnesium containing antacid ( maalox ) decreased fexofenadine auc by 41 % and cmax by 43 % .
mechanism	plasma concentrations ( auc 0 - 24 hrs ) of <e10> drug1 </e10> decreased 15 % with coadministration of <e20> drug2 </e20> relative to that observed with drug1 alone .
mechanism	<e10> drug1 </e10> is also expected to reduce plasma concentrations of other <e22> drug2 </e22> that have significant metabolism by cyp3a4 , such as lovastatin and atorvastatin .
mechanism	midazolam : <e10> drug1 </e10> increased the auc of <e20> drug2 </e20> , a sensitive cyp3a4 substrate , by # - fold on day # and # - fold on day 5 , when a single oral dose of drug2 # mg was coadministered on day # and day # of a regimen of drug1 # mg on day # and # mg / day on days # through 5 .
mechanism	[ the effect of drug1 on the renal excretion of verografin and iodamide in dogs ] the intravenous injection of <e10> drug1 </e10> in a dose of # mg / kg enhanced <e20> drug2 </e20> and iodamide excretion in chronic canine experiments .
mechanism	<e12> drug1 </e12> or sucralfate substantially interfere with the absorption of some <e22> drug2 </e22> , resulting in low urine levels .
mechanism	in the first study , concomitant administration of # mg <e10> drug1 </e10> and # g <e20> drug2 </e20> resulted in decreases of more than 22 % for auc and 40 % for cmax when compared to dosing drug1 alone .
mechanism	<e10> drug1 </e10> and clarithromycin ( and possibly other macrolide _ antibiotics ) and tetracycline may increase <e20> drug2 </e20> absorption in patients who inactivate drug2 by bacterial metabolism in the lower intestine , so that digitalis intoxication may result .
mechanism	quinidine : coadministration of a 10 - mg single dose of <e10> drug1 </e10> with <e20> drug2 </e20> ( 166 mg / day for # days ) , a potent inhibitor of cyp2d6 , increased the auc of drug1 by 112 % but decreased the auc of its active metabolite , dehydro drug1 , by 35 % .
mechanism	in a study in normal volunteers , it was found that chronic concurrent administration of # g of <e11> drug1 </e11> per day decreases <e20> drug2 </e20> blood levels approximately 20 % .
mechanism	co - administration of <e10> drug1 </e10> with <e20> drug2 </e20> produced a 25 % increase in auc and a 33 % increase in the cmax of acamprosate .
mechanism	agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of <e11> drug1 </e11> are the following : cisplatin , <e20> drug2 </e20> , felbamate , rifampin , phenobarbital , phenytoin ( 2 ) , primidone , methsuximide , and theophylline thus , if a patient has been titrated to a stable dosage on drug1 , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for drug1 may be necessary .
mechanism	drug1 : <e10> drug1 </e10> increases both free and bound <e20> drug2 </e20> by reducing the plasma clearance of drug2 to about one - third , as well as decreasing its protein binding .
mechanism	because <e12> drug1 </e12> may interfere with the absorption of <e22> drug2 </e22> , simultaneous use of these drugs should be avoided .
mechanism	this decrease in bioavailability was about 5 % when <e10> drug1 </e10> was administered # hours after <e21> drug2 </e21> .
mechanism	anticonvulsants : in a pharmacokinetic study , maximum plasma concentrations of <e10> drug1 </e10> were considerably lower in epileptic patients on long - term <e22> drug2 </e22> therapy ( eg , phenytoin , carbamazepine , or phenobarbital ) than in healthy volunteers .
mechanism	or with multivitamins containing <e10> drug1 </e10> may substantially interfere with drug absorption and result in insufficient plasma and tissue <e22> drug2 </e22> concentrations .
mechanism	systemic exposure to <e10> drug1 </e10> is expected to be increased when coadministered with <e21> drug2 </e21> .
mechanism	methotrexate : ibuprofen , as well as other <e12> drug1 </e12> , probably reduces the tubular secretion of <e20> drug2 </e20> based on in vitro studies in rabbit kidney slices .
mechanism	multivalent cation - containing products : concurrent administration of a <e12> drug1 </e12> , including ciprofloxacin , with multivalent cation - containing products such as magnesium or <e20> drug2 </e20> antacids , sucralfate , videx chewable / buffered tablets or pediatric powder , or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .
mechanism	aspirin : concurrent administration of <e11> drug1 </e11> may lower <e20> drug2 </e20> plasma levels , possibly by competing for protein - binding sites .
mechanism	increasing the drug1 dose to # mg every # hours does not compensate for the increased <e10> drug1 </e10> metabolism due to <e20> drug2 </e20> .
mechanism	anticonvulsants : in a pharmacokinetic study , maximum plasma concentrations of <e10> drug1 </e10> were considerably lower in epileptic patients on long - term anticonvulsant therapy ( eg , phenytoin , <e20> drug2 </e20> , or phenobarbital ) than in healthy volunteers .
mechanism	coadministration with <e10> drug1 </e10> ( 40 mg bid for # days ) resulted in a significant increase in <e20> drug2 </e20> plasma levels suggesting that , at these doses , drug1 is a weak inhibitor of 2d6 .
mechanism	the rate of metabolism and the leukopenic activity of <e10> drug1 </e10> reportedly are increased by chronic administration of high doses of <e20> drug2 </e20> .
mechanism	cholestyramine and colestipol resins : absorption of <e10> drug1 </e10> is impaired in the presence of <e22> drug2 </e22> .
mechanism	urinary _ acidifying _ agents ( <e10> drug1 </e10> , sodium _ acid _ phosphate , etc , ) increase the concentration of the ionized species of the <e20> drug2 </e20> molecule , thereby increasing urinary excretion .
mechanism	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma <e10> drug1 </e10> concentrations include : acute alcohol intake , amiodarone , chboramphenicol , chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , h2 - antagonists , halothane , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , <e22> drug2 </e22> , tolbutamide , trazodone
mechanism	the mean percentage increase in the <e10> drug1 </e10> auc after <e20> drug2 </e20> administration was # % ( range : # to 81 ) .
mechanism	there have been postmarketing reports of drug interactions when drug2 is coadministered with drug1 , resulting in qt prolongation , cardiac arrythmias , ventricular tachycardia , ventricular fibrulation , and torsades de pointes , most like due to inhibition of hepatic metabolism of <e10> drug1 </e10> by <e20> drug2 </e20> .
mechanism	inhibitors of cyp3a4 ( eg , ketoconazole ) or cyp2d6 ( eg , quinidine , fluoxetine , or <e10> drug1 </e10> ) can inhibit <e20> drug2 </e20> elimination and cause increased blood levels .
mechanism	in eight hiv - infected patients , the steady - state auc of drug1 was decreased an average of 26 % ( 95 % ci = 14 % , 37 % ) when <e10> drug1 </e10> was administered # hours prior to a marketed chewable / dispersible tablet formulation of <e21> drug2 </e21> .
mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of <e11> drug1 </e11> are the following : acetazolamide , azole _ antifungals , cimetidine , clarithromycin ( 1 ) , dalfopristin , danazol , delavirdine , diltiazem , erythromycin ( 1 ) , fluoxetine , fluvoxamine , grapefruit juice , isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , <e20> drug2 </e20> , protease _ inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate ( 1 ) , verapamil , zileuton .
mechanism	these studies indicate that ketoconazole or <e10> drug1 </e10> co - administration enhances <e20> drug2 </e20> gastrointestinal absorption .
mechanism	however , the systemic administration of some <e12> drug1 </e12> has been shown to elevate plasma concentrations of <e20> drug2 </e20> , interfere with the metabolism of caffeine , and enhance the effects of the oral anticoagulant warfarin and its derivatives , and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly .
mechanism	anticonvulsants ( carbamazepine , felbamate , phenobarbital , phenytoin , <e10> drug1 </e10> ) : increase the metabolism of ethinyl _ estradiol and / or some <e22> drug2 </e22> , leading to possible decrease in contraceptive effectiveness .
mechanism	drug interactions with antacids administration of # mg of <e10> drug1 </e10> ( 2 x # mg capsule ) within # minutes of an aluminum and <e20> drug2 </e20> containing antacid ( maalox ) decreased fexofenadine auc by 41 % and cmax by 43 % .
mechanism	there have been greater than two - fold increases of previously stable plasma levels of <e12> drug1 </e12> when <e20> drug2 </e20> has been administered in combination with these agents .
mechanism	valproate : <e10> drug1 </e10> causes a slight decrease ( about 10 % ) in steady - state <e20> drug2 </e20> concentrations .
mechanism	<e10> drug1 </e10> : may decrease renal tubular secretion of <e20> drug2 </e20> resulting in increased blood levels and / or drug2 toxicity .
mechanism	benzodiazepines : combination <e12> drug1 </e12> may decrease the clearance of some benzodiazepines ( alprazolam , chlordiazepoxide , diazepam ) and increase the clearance of others ( lorazepam , <e20> drug2 </e20> , temazepam ) .
mechanism	carbamazepine : <e11> drug1 </e11> causes a decrease in the steady - state <e20> drug2 </e20> plasma concentrations and an increase in the steady - state drug2 _ epoxide plasma concentration .
mechanism	ritonavir and indinavir : upon concomitant administration of # mg of <e10> drug1 </e10> with # mg bid <e20> drug2 </e20> , the cmax and auc of drug2 were reduced by approximately 20 % .
mechanism	prednisolone : <e10> drug1 </e10> may inhibit the metabolism of <e20> drug2 </e20> , leading to increased plasma concentrations .
mechanism	erythromycin : in hypercholesterolemic patients , steady - state <e10> drug1 </e10> auc and cmax increased approximately 50 % and 24 % respectively after # days with co - administration of <e20> drug2 </e20> , a known inhibitor of cytochrome p450 3a4 .
mechanism	drugs that cause significant sustained elevation in gastric ph ( histamine _ h2 - receptor _ antagonists such as ranitidine or <e10> drug1 </e10> ) may reduce plasma concentrations of <e21> drug2 </e21> and therefore potentially may reduce efficacy .
mechanism	rifampin : following concomitant administration of a single dose of <e11> drug1 </e11> to subjects receiving multiple doses of <e20> drug2 </e20> , m1 peak levels were increased ( ~ 40 % ) over those seen when drug1 was given alone .
mechanism	because oral <e12> drug1 </e12> may interfere with the hepatic metabolism of <e20> drug2 </e20> , toxic levels of the anticonvulsant may occur when an oral anticoagulant and drug2 are administered concurrently .
mechanism	this may occur because <e10> drug1 </e10> competitively displaces <e22> drug2 </e22> from protein binding sites .
mechanism	on the basis of the metabolism of drug2 by cytochrome p450 3a4 , ketoconazole , <e10> drug1 </e10> , erythromycin , gemfibrozil , grapefruit juice , and other inhibitors of cytochrome p450 3a4 would be expected to lead to an increase in plasma <e20> drug2 </e20> concentrations .
mechanism	human pharmacokinetics data indicate that oral <e10> drug1 </e10> potently inhibits the metabolism of <e20> drug2 </e20> resulting in an eight - fold increase in the mean auc of drug2 .
mechanism	studies in humans show that the absorption of <e10> drug1 </e10> as reflected in urinary excretion is markedly decreased even when administered one hour before <e20> drug2 </e20> .
mechanism	when used in therapeutic doses , <e10> drug1 </e10> had a modest effect on the pharmacokinetics of atorvastatin , carbamazepine , cetirizine , didanosine , efavirenz , fluconazole , indinavir , midazolam , <e20> drug2 </e20> , sildenafil , theophylline ( intravenous and oral ) , triazolam , trimethoprim / sulfamethoxazole or zidovudine .
mechanism	interactions with other antiretroviral _ drugs : significant decreases in the auc of <e10> drug1 </e10> ( 20 % ) and indinavir ( 84 % ) occurred following simultaneous administration of these agents with <e21> drug2 </e21> .
mechanism	amphotericin , foscarnet , and aminoglycosides : drugs such as amphotericin , foscarnet , and <e12> drug1 </e12> may increase the risk of developing peripheral neuropathy or other hivid - associated adverse events by interfering with the renal clearance of <e20> drug2 </e20> ( thereby raising systemic exposure ) .
mechanism	drugs which inhibit cyp 3a4 ( e , g , , <e10> drug1 </e10> , macrolide _ antibiotics such as erythromycin ) have the potential to result in increased plasma concentrations of <e22> drug2 </e22> .
mechanism	other potentially important drug interactions : drug1 : <e12> drug1 </e12> metabolized by hepatic oxidation ( e , g , , alprazolam , midazolam , triazolam elc , ) should be used with caution because the clearance of these drugs is likely to be reduced by <e20> drug2 </e20> .
mechanism	coadministration with compounds that are potent inducers of cyp3a4 ( eg , phenobarbital , <e10> drug1 </e10> , dexamethasone , carbamazepine ) may result in decreased plasma levels of <e20> drug2 </e20> .
mechanism	<e10> drug1 </e10> has been reported to decrease the clearance of <e20> drug2 </e20> and midazolam and thus may increase the pharmacologic effect of these benzodiazepines .
mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of <e11> drug1 </e11> are the following : <e20> drug2 </e20> , azole _ antifungals , cimetidine , clarithromycin ( 1 ) , dalfopristin , danazol , delavirdine , diltiazem , erythromycin ( 1 ) , fluoxetine , fluvoxamine , grapefruit juice , isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease _ inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate ( 1 ) , verapamil , zileuton .
mechanism	phenytoin , <e10> drug1 </e10> , and rifampin may decrease <e20> drug2 </e20> plasma levels , resulting in a decrease in effectiveness of a previously effective drug2 dose .
mechanism	drug1 : <e10> drug1 </e10> causes an approximate 50 % increase in the clearance of <e21> drug2 </e21> at steady state and , therefore , the addition of carbamazepine results in an approximate 40 % decrease in the steady - state trough concentrations of drug2 as compared to the same dose of drug2 given as monotherapy .
mechanism	co - administration of <e10> drug1 </e10> decreased the plasma concentrations of <e20> drug2 </e20> by approximately 40 % .
mechanism	hepatic enzyme inducers , inhibitors and substrates : drugs which induce cytochrome p450 3a4 ( cyp 3a4 ) enzyme activity ( e , g , , barbiturates , phenytoin , <e10> drug1 </e10> , rifampin ) may enhance the metabolism of <e22> drug2 </e22> and require that the dosage of the corticosteroid be increased .
mechanism	acidifying _ agents : gastrointestinal _ acidifying _ agents ( <e10> drug1 </e10> , reserpine , glutamic _ acid _ hcl , ascorbic _ acid , fruit juices , etc , ) lower absorption of <e20> drug2 </e20> .
mechanism	anticonvulsants : in a pharmacokinetic study , maximum plasma concentrations of <e10> drug1 </e10> were considerably lower in epileptic patients on long - term anticonvulsant therapy ( eg , phenytoin , carbamazepine , or <e20> drug2 </e20> ) than in healthy volunteers .
mechanism	tricyclic _ antidepressants ( <e10> drug1 </e10> , imipramine , nortriptyline ) : metabolism may be inhibited by <e22> drug2 </e22> , increasing plasma levels of antidepressant ;
mechanism	<e10> drug1 </e10> tablets may alter the metabolism of cyclosporine , tacrolimus , and <e20> drug2 </e20> , resulting in elevated plasma concentrations of the latter drugs .
mechanism	limited data in patients receiving known enzyme inducers ( phenytoin , phenobarbital , <e10> drug1 </e10> ) indicate only a 30 % increase in the rate of <e20> drug2 </e20> elimination .
mechanism	ethosuximide : <e12> drug1 </e12> may delay intestinal absorption of <e20> drug2 </e20> .
mechanism	caffeine theobromine grepafloxacin , like other <e12> drug1 </e12> , may inhibit the metabolism of caffeine and <e20> drug2 </e20> .
mechanism	other potentially important drug interactions : benzodiazepines : benzodiazepines metabolized by hepatic oxidation ( e , g , , <e10> drug1 </e10> , midazolam , triazolam elc , ) should be used with caution because the clearance of these drugs is likely to be reduced by <e20> drug2 </e20> .
mechanism	antacids or h _ 2 _ receptor _ antagonists : when <e10> drug1 </e10> is administered immediately following antacids or <e22> drug2 </e22> , the absorption of drug1 is slightly enhanced .
mechanism	binding to serum proteins : the following agents may either inhibit <e10> drug1 </e10> binding to serum proteins or alter the concentrations of serum binding proteins : androgens and related anabolic _ hormones , asparaginase , clofibrate , estrogens and estrogen - containing _ compounds , <e20> drug2 </e20> , furosemide , glucocorticoids , meclofenamic _ acid , mefenamic _ acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen .
mechanism	the auc of drug1 was decreased an average of 15 - fold in # healthy subjects given <e10> drug1 </e10> and <e20> drug2 </e20> - placebo tablets concurrently .
mechanism	although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 ( eg , calcium _ channel _ blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot _ derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , <e10> drug1 </e10> , and triazolam ) may have elevated plasma concentrations when coadministered with <e20> drug2 </e20> ;
mechanism	we propose these pharmacokinetic changes to be the underlying mechanism for the reduction of oral <e10> drug1 </e10> cytotoxicity by <e23> drug2 </e23> .
mechanism	( 1968 , 1970 ) , the higher serum concentrations of <e12> drug1 </e12> and cephaloridine reached after administration of <e20> drug2 </e20> are due not only to slower renal elimination but also to an altered distribution in the body .
mechanism	although <e10> drug1 </e10> may increase the bioavailability of <e20> drug2 </e20> by increasing gastric emptying , drug1 may also adversely affect disease control by its dopamine receptor antagonistic properties .
mechanism	although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 ( eg , calcium _ channel _ blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , <e10> drug1 </e10> , tacrolimus , cyclosporine , ergot _ derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with <e20> drug2 </e20> ;
mechanism	- drug1 : <e10> drug1 </e10> blunts the increases in urine volume and sodium excretion seen during <e20> drug2 </e20> treatment and inhibits the drug2 - induced increase in plasma renin activity .
mechanism	in a multiple - dose study , <e10> drug1 </e10> caused a dose - related increase in the mean elimination half - life of <e20> drug2 </e20> , thereby decreasing the clearance of drug2 by up to 80 % and leading to a five - fold increase in the auc and the half - life of drug2 .
mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of <e11> drug1 </e11> are the following : acetazolamide , azole _ antifungals , cimetidine , clarithromycin ( 1 ) , dalfopristin , danazol , delavirdine , diltiazem , erythromycin ( 1 ) , fluoxetine , fluvoxamine , grapefruit juice , isoniazid , itraconazole , <e20> drug2 </e20> , loratadine , nefazodone , niacinamide , nicotinamide , protease _ inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate ( 1 ) , verapamil , zileuton .
mechanism	however , other published reports describe modest elevations ( less than two - fold ) of drug1 and metabolite concentrations when <e10> drug1 </e10> was taken with paroxetine , <e20> drug2 </e20> , and sertraline .
mechanism	plasma levels of several closely related tricyclic _ antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors ( e , g , , cimetidine , <e10> drug1 </e10> ) and decreased by the concomitant administration of hepatic enzyme inducers ( e , g , , barbiturates , phenytoin ) , and such an effect may be anticipated with <e20> drug2 </e20> as well .
mechanism	urinary alkalinizing agents ( acetazolamide , some <e12> drug1 </e12> ) increase the concentration of the non - ionized species of the <e20> drug2 </e20> molecule , thereby decreasing urinary excretion .
mechanism	barbiturates , <e10> drug1 </e10> , or rifampin increased metabolic clearance of <e20> drug2 </e20> because of the induction of hepatic enzymes .
mechanism	the following are examples of drugs known to inhibit the metabolism of other related <e12> drug1 </e12> , presumably through inhibition of cyp3a : nefazodone , fluvoxamine , cimetidine , diltiazem , <e20> drug2 </e20> , and some macrolide _ antibiotics .
mechanism	although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 ( eg , <e12> drug1 </e12> , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot _ derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with <e20> drug2 </e20> ;
mechanism	this study demonstrates that concurrent administration of <e10> drug1 </e10> permits at least a twofold increase in dose and total exposure to <e20> drug2 </e20> .
mechanism	there is a single case report , which suggests that <e10> drug1 </e10> may interfere with <e20> drug2 </e20> absorption .
mechanism	drugs which induce cyp3a4 activity ( eg , phenobarbital , rifampin , <e10> drug1 </e10> ) would be expected to increase the clearance of <e20> drug2 </e20> resulting in lowered plasma concentrations .
mechanism	chlorpropamide : chlorpropamide s plasma half - life may be prolonged by drug1 , since <e10> drug1 </e10> and <e20> drug2 </e20> may compete for excretion in the renal tubule .
mechanism	substances that are potent inhibitors of cyp3a4 activity ( eg , ketoconazole and <e10> drug1 </e10> ) decrease <e20> drug2 </e20> metabolism and increase drug2 plasma concentrations .
mechanism	the half - life of <e10> drug1 </e10> in plasma and brain was longer in the presence of <e20> drug2 </e20> than when drug1 was given alone .
mechanism	cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation , the discontinuance of <e10> drug1 </e10> resin could pose a hazard to health if a potentially toxic drug such as <e22> drug2 </e22> has been filtrated to a maintenance level while the patient was taking drug1 resin .
mechanism	antacids ( aluminum - or magnesium - containing ) : concomitant administration of 300 - mg <e10> drug1 </e10> capsules with # ml <e21> drug2 </e21> suspension reduces the rate ( cmax ) and extent ( auc ) of absorption by approximately 40 % .
mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of <e11> drug1 </e11> are the following : acetazolamide , azole _ antifungals , <e20> drug2 </e20> , clarithromycin ( 1 ) , dalfopristin , danazol , delavirdine , diltiazem , erythromycin ( 1 ) , fluoxetine , fluvoxamine , grapefruit juice , isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease _ inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate ( 1 ) , verapamil , zileuton .
mechanism	uricosuric _ drugs , such as probenecid and <e10> drug1 </e10> , can inhibit renal tubular secretion of <e20> drug2 </e20> .
mechanism	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma <e10> drug1 </e10> concentrations include : acute alcohol intake , amiodarone , chboramphenicol , chlordiazepoxide , cimetidine , diazepam , dicumarol , disulfiram , estrogens , ethosuximide , fluoxetine , h2 - antagonists , <e20> drug2 </e20> , isoniazid , methylphenidate , phenothiazines , phenylbutazone , salicylates , succinimides , sulfonamides , tolbutamide , trazodone
mechanism	cimetidine : co - administration with high doses of <e10> drug1 </e10> [ 800 mg twice daily ] increased the cmax of <e20> drug2 </e20> by 21 % , the auc0 - 120hr by 23 % and the t1 / 2 by 15 % .
mechanism	plasma levels of several closely related <e12> drug1 </e12> have been reported to be increased by the concomitant administration of <e20> drug2 </e20> or hepatic enzyme inhibitors ( e , g , , cimetidine , fluoxetine ) and decreased by the concomitant administration of hepatic enzyme inducers ( e , g , , barbiturates , phenytoin ) , and such an effect may be anticipated with cmi as well .
mechanism	morphine : a literature article reported that when a 60 - mg controlled - release <e10> drug1 </e10> capsule was administered # hours prior to a 600 - mg <e21> drug2 </e21> capsule ( n = 12 ) , mean gabapentin auc increased by 44 % compared to gabapentin administered without drug1 .
mechanism	plasma concentrations of <e12> drug1 </e12> are decreased when administered with antacids containing magnesium , calcium , or <e20> drug2 </e20> .
mechanism	binding to serum proteins : the following agents may either inhibit <e10> drug1 </e10> binding to serum proteins or alter the concentrations of serum binding proteins : <e22> drug2 </e22> and related anabolic _ hormones , asparaginase , clofibrate , estrogens and estrogen - containing _ compounds , 5 - fluorouracil , furosemide , glucocorticoids , meclofenamic _ acid , mefenamic _ acid , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen .
mechanism	in vitro studies have shown <e11> drug1 </e11> can displace <e22> drug2 </e22> s , such as warfarin , from their protein - binding sites .
mechanism	multivalent cation - containing products : concurrent administration of a <e12> drug1 </e12> , including ciprofloxacin , with multivalent cation - containing products such as magnesium or aluminum antacids , sucralfate , videx chewable / buffered tablets or pediatric powder , or products containing <e20> drug2 </e20> , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .
mechanism	drugs that inhibit cytochrome p450iid6 , such as <e10> drug1 </e10> , might increase the plasma concentrations of <e20> drug2 </e20> in patients that are on chronic drug2 therapy ;
mechanism	antacids : in a clinical pharmacology study , coadministration of an antacid ( <e10> drug1 </e10> , magnesium _ hydroxide , and simethicone ) with <e20> drug2 </e20> reduced serum levels and urinary excretion of drug2 at as compared with drug2 administered alone , suggesting that antacids may impair absorption of drug2 .
mechanism	antacids and sucralfate : sucralfate and antacids containing magnesium or <e10> drug1 </e10> , as well as formulations containing divalent and trivalent cations such as videx ( didanosine ) , chewable / buffered tablets or the pediatric powder for oral solution can form chelation complexes with <e20> drug2 </e20> and interfere with its bioavailability .
mechanism	levothyroxine _ sodium absorption : the following agents may bind and decrease absorption of <e10> drug1 </e10> from the gastrointestinal tract : aluminum _ hydoxide , cholestyramine resin , colestipol _ hydrochloride , ferrous _ sulfate , sodium _ polystyrene _ sulfonate , soybean flour ( e , g , , infant formula ) , <e20> drug2 </e20> .
mechanism	protease _ inhibitors : <e10> drug1 </e10> , lopinavir , nelfinavir , and ritonavir have been shown to decrease plasma levels of <e22> drug2 </e22> ;
mechanism	since zarontin ( drug2 ) may interact with concurrently administered antiepileptic _ drugs , periodic serum level determinations of these drugs may be necessary ( eg , drug2 may elevate phenytoin serum levels and <e10> drug1 </e10> has been reported to both increase and decrease <e20> drug2 </e20> levels ) .
mechanism	phenobarbital : <e12> drug1 </e12> may delay intestinal absorption of <e20> drug2 </e20> ;
mechanism	multivalent cation - containing products : concurrent administration of a <e12> drug1 </e12> , including ciprofloxacin , with multivalent cation - containing products such as magnesium or aluminum antacids , sucralfate , <e21> drug2 </e21> chewable / buffered tablets or pediatric powder , or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .
mechanism	previous studies have demonstrated a significant reduction in the oral bioavailability of <e10> drug1 </e10> and ciprofloxacin when administered concomitantly with an intravenous opiate such as <e20> drug2 </e20> .
mechanism	the plasma concentration of <e10> drug1 </e10> has been reported to be increased by the concomitant administration of <e20> drug2 </e20> ;
mechanism	pharmacokinetic studies have demonstrated that omeprazole and <e10> drug1 </e10> significantly increased the systemic exposure of <e20> drug2 </e20> and / or its major metabolites .
mechanism	antacid ( drug1 ) : <e11> drug1 </e11> reduced the bioavailability of <e20> drug2 </e20> ( n = 16 ) by about 20 % .
mechanism	levothyroxine _ sodium absorption : the following agents may bind and decrease absorption of <e10> drug1 </e10> from the gastrointestinal tract : aluminum _ hydoxide , <e20> drug2 </e20> resin , colestipol _ hydrochloride , ferrous _ sulfate , sodium _ polystyrene _ sulfonate , soybean flour ( e , g , , infant formula ) , sucralfate .
mechanism	results : the geometric mean ( 90 % confidence interval ) whole blood <e10> drug1 </e10> area under the plasma concentration time - curve increased 60 % ( 35 % - 90 % ) , from # to # ng x h / ml , and maximum concentration increased 43 % ( 14 % - 81 % ) , from # to # ng / ml , with <e20> drug2 </e20> coadministration , whereas the mean elimination half - life of drug1 decreased slightly , from # to # hours .
mechanism	the mechanism for this interaction probably is adsorption of <e10> drug1 </e10> onto the surface of <e20> drug2 </e20> .
mechanism	drug1 : <e10> drug1 </e10> may inhibit both synthetic and catabolic enzymes of <e22> drug2 </e22> .
mechanism	binding to serum proteins : the following agents may either inhibit <e10> drug1 </e10> binding to serum proteins or alter the concentrations of serum binding proteins : androgens and related anabolic _ hormones , asparaginase , clofibrate , estrogens and estrogen - containing _ compounds , 5 - fluorouracil , furosemide , glucocorticoids , meclofenamic _ acid , <e20> drug2 </e20> , methadone , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen .
mechanism	naproxen , naproxen _ sodium and other <e12> drug1 </e12> have been reported to reduce the tubular secretion of <e20> drug2 </e20> in an animal model , possibly increasing the toxicity of drug2 .
mechanism	<e10> drug1 </e10> has been reported to decrease the clearance of triazolam and <e20> drug2 </e20> and thus may increase the pharmacologic effect of these benzodiazepines .
mechanism	cytochrome p - 450 inducers , such as phenytoin , carbamazepine and <e10> drug1 </e10> , induce <e20> drug2 </e20> metabolism , causing an approximately 30 % decrease in plasma drug2 levels .
mechanism	in clinical trials , drug2 was used with drug1 , diuretics , anticoagulants , oral vasodilators , and supplemental oxygen , in a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or <e10> drug1 </e10> in whom therapy with <e21> drug2 </e21> was initiated , apparent oral clearance values for furosemide ( n = 23 ) and drug1 ( n = 30 ) were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
mechanism	urinary _ acidifying _ agents ( ammonium _ chloride , <e10> drug1 </e10> , etc , ) increase the concentration of the ionized species of the <e20> drug2 </e20> molecule , thereby increasing urinary excretion .
mechanism	probenecid or cimetidine : concomitant administration of <e10> drug1 </e10> or cimetidine decreases the elimination of <e20> drug2 </e20> , most likely by inhibition of renal tubular secretion of drug2 .
mechanism	effects of other antiepileptic _ drugs on drug2 phenytoin : phenytoin causes an approximate doubling of the clearance of drug2 ( felbamate ) at steady state and , therefore , the addition of <e10> drug1 </e10> causes an approximate 45 % decrease in the steady - state trough concentrations of <e21> drug2 </e21> as compared to the same dose of drug2 given as monotherapy .
mechanism	phenytoin : <e12> drug1 </e12> may delay intestinal absorption of <e20> drug2 </e20> ;
mechanism	interactions for vitamin _ d _ analogues ( vitamin _ d2 , vitamin _ d3 , calcitriol , and calcidiol ) : drug1 : <e10> drug1 </e10> has been reported to reduce intestinal absorption of <e22> drug2 </e22> ;
mechanism	<e10> drug1 </e10> : may increase cyp metabolism of <e22> drug2 </e22> leading to possible decrease in contraceptive effectiveness .
mechanism	drug1 : <e10> drug1 </e10> increases the metabolism of ethinyl _ estradiol and some progestins ( <e20> drug2 </e20> ) resulting in decreased contraceptive effectiveness and increased menstrual irregularities .
mechanism	use with allopurinol : the principal pathway for detoxification of <e10> drug1 </e10> is inhibited by <e20> drug2 </e20> .
mechanism	conclusions : single - dose <e10> drug1 </e10> coadministration leads to higher <e20> drug2 </e20> exposure , presumably by inhibition of the first - pass metabolism of drug2 .
mechanism	there have been greater than 2 - fold increases in previously stable plasma levels of other antidepressants , including <e10> drug1 </e10> , when <e20> drug2 </e20> has been administered in combination with these agents .
mechanism	protease _ inhibitors : amprenavir , lopinavir , nelfinavir , and <e10> drug1 </e10> have been shown to decrease plasma levels of <e22> drug2 </e22> ;
mechanism	other potentially important drug interactions : benzodiazepines : benzodiazepines metabolized by hepatic oxidation ( e , g , , alprazolam , <e10> drug1 </e10> , triazolam elc , ) should be used with caution because the clearance of these drugs is likely to be reduced by <e20> drug2 </e20> .
mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of <e11> drug1 </e11> are the following : acetazolamide , azole _ antifungals , cimetidine , clarithromycin ( 1 ) , dalfopristin , danazol , delavirdine , <e20> drug2 </e20> , erythromycin ( 1 ) , fluoxetine , fluvoxamine , grapefruit juice , isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease _ inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate ( 1 ) , verapamil , zileuton .
mechanism	other strong selective cyp3a4 inhibitors such as <e10> drug1 </e10> can also be expected to increase the exposure of <e20> drug2 </e20> .
mechanism	the immediate release , but not the coat - core formulation of <e10> drug1 </e10> increased plasma <e20> drug2 </e20> concentrations by about 20 % .
mechanism	agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of <e11> drug1 </e11> are the following : cisplatin , doxorubicin _ hcl , felbamate , rifampin , <e20> drug2 </e20> , phenytoin ( 2 ) , primidone , methsuximide , and theophylline thus , if a patient has been titrated to a stable dosage on drug1 , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for drug1 may be necessary .
mechanism	in an in vitro study in human liver microsomes , inhibition of cyp2a6 hydroxylation of <e12> drug1 </e12> by <e20> drug2 </e20> ( 200 m m m i , e , , # mg / l ) was 17 - 28 % .
mechanism	pharmacokinetic studies have demonstrated that <e10> drug1 </e10> and erythromycin significantly increased the systemic exposure of <e20> drug2 </e20> and / or its major metabolites .
mechanism	in renal and cardiac transplant recipients , a reduction of <e10> drug1 </e10> dose ranging from 15 % to 48 % was necessary to maintain drug1 trough concentrations similar to those seen prior to the addition of <e20> drug2 </e20> .
mechanism	although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 ( eg , calcium _ channel _ blockers , dapsone , disopyramide , quinine , <e10> drug1 </e10> , quinidine , warfarin , tacrolimus , cyclosporine , ergot _ derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with <e20> drug2 </e20> ;
mechanism	although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 ( eg , calcium _ channel _ blockers , dapsone , disopyramide , quinine , amiodarone , <e10> drug1 </e10> , warfarin , tacrolimus , cyclosporine , ergot _ derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with <e20> drug2 </e20> ;
mechanism	quinolone _ antibiotic s : videx should be administered at least # hours after or # hours before dosing with drug1 because plasma concentrations of <e10> drug1 </e10> are decreased when administered with antacids containing <e20> drug2 </e20> , calcium , or aluminum .
mechanism	antibiotics : <e12> drug1 </e12> have been reported to cause a significant decrease in <e22> drug2 </e22> clearance .
mechanism	in vitro studies indicate that , at therapeutic concentrations of <e12> drug1 </e12> ( 300 m g / ml ) , the binding of <e20> drug2 </e20> was reduced from approximately # % to # % , representing a potential twofold increase in unbound drug2 plasma levels .
mechanism	ketoconazole : when a single 125 - mg dose of <e10> drug1 </e10> was administered on day5 of a 10 - day regimen of # mg / day of <e20> drug2 </e20> , a strong cyp3a4 inhibitor , the auc of aprepitant increased approximately 5 - fold and the mean terminal half - life of aprepitant increased approximately 3 - fold .
mechanism	<e10> drug1 </e10> salts may reduce the bioavailability of carbidopa and <e20> drug2 </e20> .
mechanism	<e11> drug1 </e11> concentrations were equivocally higher when given with <e20> drug2 </e20> , but this is not likely to be clinically important .
mechanism	phenobarbital : <e12> drug1 </e12> may delay intestinal absorption of <e20> drug2 </e20> ;
mechanism	this increase is due to the inhibition of <e10> drug1 </e10> metabolism via p450 2c9 by <e20> drug2 </e20> ( see clinical pharmacology - pharmacokinetics : metabolism ) .
mechanism	although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 ( eg , calcium _ channel _ blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , <e12> drug1 </e12> , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with <e20> drug2 </e20> ;
mechanism	human _ growth _ hormone - concomitant use of <e10> drug1 </e10> and <e20> drug2 </e20> may enhance nutrient absorption in those with severe short bowel syndrome .
mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of <e11> drug1 </e11> are the following : acetazolamide , azole _ antifungals , cimetidine , clarithromycin ( 1 ) , dalfopristin , danazol , delavirdine , diltiazem , <e20> drug2 </e20> ( 1 ) , fluoxetine , fluvoxamine , grapefruit juice , isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease _ inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate ( 1 ) , verapamil , zileuton .
mechanism	binding to serum proteins : the following agents may either inhibit <e10> drug1 </e10> binding to serum proteins or alter the concentrations of serum binding proteins : androgens and related anabolic _ hormones , asparaginase , clofibrate , estrogens and estrogen - containing _ compounds , 5 - fluorouracil , furosemide , glucocorticoids , meclofenamic _ acid , mefenamic _ acid , <e20> drug2 </e20> , perphenazine , phenylbutazone , phenytoin , salicylates , tamoxifen .
mechanism	although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 ( eg , calcium _ channel _ blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot _ derivatives , pimozide , <e10> drug1 </e10> , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with <e20> drug2 </e20> ;
mechanism	co - administration with efavirenz or <e10> drug1 </e10> had a modest effect on the pharmacokinetics of <e20> drug2 </e20> .
mechanism	oral contraceptives : coadministration of <e10> drug1 </e10> and an oral <e22> drug2 </e22> increased auc values for norethindrone and ethinyl _ estradiol by approximately 30 % and 20 % .
mechanism	coadministration of <e10> drug1 </e10> # mg and <e20> drug2 </e20> , a cyp2c19 substrate , resulted in a 45 % decrease in clearance of drug2 .
mechanism	drugs that cause significant sustained elevation in gastric ph ( <e12> drug1 </e12> such as ranitidine or cimetidine ) may reduce plasma concentrations of <e21> drug2 </e21> and therefore potentially may reduce efficacy .
mechanism	caffeine theobromine grepafloxacin , like other <e12> drug1 </e12> , may inhibit the metabolism of <e20> drug2 </e20> and theobromine .
mechanism	agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of <e11> drug1 </e11> are the following : cisplatin , doxorubicin _ hcl , felbamate , rifampin , phenobarbital , phenytoin ( 2 ) , primidone , methsuximide , and <e20> drug2 </e20> thus , if a patient has been titrated to a stable dosage on drug1 , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for drug1 may be necessary .
mechanism	consequently , the effect of <e10> drug1 </e10> on the retention of <e20> drug2 </e20> was lower than on absorption .
mechanism	inhibitors of cyp3a4 ( eg , <e10> drug1 </e10> ) or cyp2d6 ( eg , quinidine , fluoxetine , or paroxetine ) can inhibit <e20> drug2 </e20> elimination and cause increased blood levels .
mechanism	<e10> drug1 </e10> at # mg bid decreased the bioavailability ( auc ) of <e20> drug2 </e20> by 26 % , but not the peak concentration .
mechanism	based on total <e10> drug1 </e10> concentrations , <e20> drug2 </e20> increased the auc by 25 % and reduced the plasma and renal clearances by 20 % and 35 % , respectively .
mechanism	anticonvulsants ( carbamazepine , felbamate , phenobarbital , phenytoin , <e10> drug1 </e10> ) : increase the metabolism of <e20> drug2 </e20> and / or some progestins , leading to possible decrease in contraceptive effectiveness .
mechanism	although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 ( eg , calcium _ channel _ blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot _ derivatives , <e10> drug1 </e10> , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with <e20> drug2 </e20> ;
mechanism	multivalent cation - containing products : concurrent administration of a quinolone , including <e10> drug1 </e10> , with multivalent cation - containing products such as magnesium or aluminum antacids , sucralfate , <e21> drug2 </e21> chewable / buffered tablets or pediatric powder , or products containing calcium , iron , or zinc may substantially decrease the absorption of drug1 , resulting in serum and urine levels considerably lower than desired .
mechanism	cyclosporin : after introduction of <e10> drug1 </e10> ( oral form ) , a sudden increase in serum <e20> drug2 </e20> level has been reported .
mechanism	drug1 : <e10> drug1 </e10> s plasma half - life may be prolonged by <e20> drug2 </e20> , since drug2 and chlorpropamide may compete for excretion in the renal tubule .
mechanism	coadministration with compounds that are potent inducers of cyp3a4 ( eg , <e10> drug1 </e10> , phenytoin , dexamethasone , carbamazepine ) may result in decreased plasma levels of <e20> drug2 </e20> .
mechanism	in a placebo - controlled trial in normal volunteers , the administration of a single # mg dose of <e10> drug1 </e10> on day # of a four - day regimen of oral <e20> drug2 </e20> ( 400 mg twice daily ) resulted in a 10 % increase in mean auc of drug1 ( p = # ) , and a slight but not statistically significant increase in mean cmax and mean half - life of drug1 .
mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of <e11> drug1 </e11> are the following : acetazolamide , azole _ antifungals , cimetidine , clarithromycin ( 1 ) , dalfopristin , danazol , delavirdine , diltiazem , erythromycin ( 1 ) , fluoxetine , fluvoxamine , grapefruit juice , isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease _ inhibitors , propoxyphene , quinine , <e20> drug2 </e20> , troleandomycin , valproate ( 1 ) , verapamil , zileuton .
mechanism	cyclosporine , digoxin , methotrexate <e11> drug1 </e11> , like other nsaids , through effects on renal prostaglandins , may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine , digoxin , <e20> drug2 </e20> , and increased toxicity .
mechanism	previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and <e10> drug1 </e10> when administered concomitantly with an intravenous opiate such as <e20> drug2 </e20> .
mechanism	anticonvulsants ( carbamazepine , <e10> drug1 </e10> , phenobarbital , phenytoin , topiramate ) : increase the metabolism of ethinyl _ estradiol and / or some <e22> drug2 </e22> , leading to possible decrease in contraceptive effectiveness .
mechanism	agents with increased levels in the presence of carbamazepine : <e11> drug1 </e11> increases the plasma levels of the following agents : clomipramine _ hcl , phenytoin ( 6 ) , and <e20> drug2 </e20> thus , if a patient has been titrated to a stable dosage on one of the agents in this category , and then begins a course of the treatment with drug1 , it is reasonable to expect that a dose decrease for the concomitant agent may be necessary .
mechanism	concomitant administration of fenofibrate ( equivalent to # mg <e11> drug1 </e11> ) with <e20> drug2 </e20> ( 20 mg ) once daily for # days resulted in approximately 17 % decrease ( range from 67 % decrease to 44 % increase ) in drug2 auc values in # healthy males .
mechanism	a pharmacokinetic study evaluating the administration of a single dose of <e11> drug1 </e11> # mg with <e20> drug2 </e20> # mg bid , a potent inhibitor of the cyp3a4 pathway , showed a # - fold increase in cmax of eplerenone and a # - fold increase in auc of eplerenone .
mechanism	clofibric _ acid : combination <e12> drug1 </e12> may increase the clearance of <e23> drug2 </e23> .
mechanism	probenecid : as with other b - lactam _ antibiotics , renal excretion of <e10> drug1 </e10> is inhibited by <e20> drug2 </e20> and resulted in an approximate 80 % increase in the auc for drug1 .
mechanism	antacids and sucralfate : sucralfate and antacids containing magnesium or aluminum , as well as formulations containing divalent and trivalent cations such as videx ( <e10> drug1 </e10> ) , chewable / buffered tablets or the pediatric powder for oral solution can form chelation complexes with <e20> drug2 </e20> and interfere with its bioavailability .
mechanism	amphotericin , foscarnet , and aminoglycosides : drugs such as <e10> drug1 </e10> , foscarnet , and aminoglycosides may increase the risk of developing peripheral neuropathy or other hivid - associated adverse events by interfering with the renal clearance of <e20> drug2 </e20> ( thereby raising systemic exposure ) .
mechanism	steroids enhance the renal toxicity of edetate _ calcium _ disodium in animals , # <e10> drug1 </e10> interferes with the action of <e20> drug2 </e20> preparations by chelating the zinc , 7
mechanism	cimetidine , ranitidine : in normal volunteers ( n = 9 ) , pretreatment with drug2 or ranitidine did not affect drug1 pharmacokinetics except that a small ( 13 % ) but statistically significant increase in the area under the serum concentration curve of <e10> drug1 </e10> resulted with <e20> drug2 </e20> .
mechanism	protease _ inhibitors : amprenavir , lopinavir , <e10> drug1 </e10> , and ritonavir have been shown to decrease plasma levels of <e22> drug2 </e22> ;
mechanism	uricosuric _ drugs , such as <e10> drug1 </e10> and sulfinpyrazone , can inhibit renal tubular secretion of <e20> drug2 </e20> .
mechanism	cytochrome p - 450 inducers , such as phenytoin , <e10> drug1 </e10> and phenobarbital , induce <e20> drug2 </e20> metabolism , causing an approximately 30 % decrease in plasma drug2 levels .
mechanism	however , in another study in healthy volunteers , the pharmacokinetics of butorphanol were significantly altered ( 29 % decrease in auc and 38 % decrease in cmax ) when a 1 - mg dose of <e11> drug1 </e11> was administered # minute after a 20 - mg dose of <e20> drug2 </e20> nasal spray .
mechanism	coadministration of <e10> drug1 </e10> significantly decreased <e20> drug2 </e20> plasma concentrations .
mechanism	the increase of <e10> drug1 </e10> level , however , is small ( 15 % ) when given with <e21> drug2 </e21> .
mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of <e11> drug1 </e11> are the following : acetazolamide , azole _ antifungals , cimetidine , clarithromycin ( 1 ) , dalfopristin , danazol , <e20> drug2 </e20> , diltiazem , erythromycin ( 1 ) , fluoxetine , fluvoxamine , grapefruit juice , isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease _ inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , valproate ( 1 ) , verapamil , zileuton .
mechanism	interactions with other antiretroviral _ drugs : significant decreases in the auc of delavirdine ( 20 % ) and <e10> drug1 </e10> ( 84 % ) occurred following simultaneous administration of these agents with <e21> drug2 </e21> .
mechanism	valproate : a recent case study has shown a possible increase in the plasma level of <e10> drug1 </e10> when co administered with <e20> drug2 </e20> .
mechanism	<e10> drug1 </e10> ( 500 mg t , i , d ) produced a 4 - fold increase in <e20> drug2 </e20> auc and a 3 - fold increase in cmax when co - administered with vardenafil # mg in healthy volunteers .
mechanism	- cholestyramine and drug1 resins : cholestytamine and <e10> drug1 </e10> resins have the potential of binding <e22> drug2 </e22> and reducing diuretic absorption from the gastrointestinal tract
mechanism	however , in a study of # normal subjects , concurrent administration of <e11> drug1 </e11> decreased <e20> drug2 </e20> protein binding and increased drug2 plasma clearance from # l / kg / h without drug1 to # l / kg / h with drug1 .
mechanism	this small decrease in excretion of <e10> drug1 </e10> by <e20> drug2 </e20> is not expected to be of clinical importance .
mechanism	when intravenous drug2 and drug1 were concomitantly administered in normal subjects , no effect on drug2 blood levels was seen , but <e11> drug1 </e11> steady - state blood levels were increased by 46 % in the presence of <e20> drug2 </e20> .
mechanism	levothyroxine _ sodium absorption : the following agents may bind and decrease absorption of <e10> drug1 </e10> from the gastrointestinal tract : aluminum _ hydoxide , cholestyramine resin , colestipol _ hydrochloride , <e20> drug2 </e20> , sodium _ polystyrene _ sulfonate , soybean flour ( e , g , , infant formula ) , sucralfate .
mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of <e11> drug1 </e11> are the following : acetazolamide , azole _ antifungals , cimetidine , clarithromycin ( 1 ) , dalfopristin , danazol , delavirdine , diltiazem , erythromycin ( 1 ) , fluoxetine , fluvoxamine , grapefruit juice , isoniazid , itraconazole , ketoconazole , loratadine , nefazodone , niacinamide , nicotinamide , protease _ inhibitors , propoxyphene , quinine , quinupristin , troleandomycin , <e20> drug2 </e20> ( 1 ) , verapamil , zileuton .
mechanism	cimetidine , caffeine , and <e10> drug1 </e10> may increase plasma levels of <e20> drug2 </e20> , potentially resulting in adverse effects .
mechanism	antacids : in a clinical pharmacology study , coadministration of an antacid ( aluminum _ hydroxide , <e10> drug1 </e10> , and simethicone ) with <e20> drug2 </e20> reduced serum levels and urinary excretion of drug2 at as compared with drug2 administered alone , suggesting that antacids may impair absorption of drug2 .
mechanism	erythromycin and clarithromycin ( and possibly other <e12> drug1 </e12> ) and tetracycline may increase <e20> drug2 </e20> absorption in patients who inactivate drug2 by bacterial metabolism in the lower intestine , so that digitalis intoxication may result .
mechanism	agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of <e11> drug1 </e11> are the following : cisplatin , doxorubicin _ hcl , felbamate , rifampin , phenobarbital , phenytoin ( 2 ) , <e20> drug2 </e20> , methsuximide , and theophylline thus , if a patient has been titrated to a stable dosage on drug1 , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for drug1 may be necessary .
mechanism	methenamine therapy : urinary excretion of <e10> drug1 </e10> is increased , and efficacy is reduced , by <e22> drug2 </e22> used in methenamine therapy .
mechanism	binding to serum proteins : the following agents may either inhibit <e10> drug1 </e10> binding to serum proteins or alter the concentrations of serum binding proteins : androgens and related anabolic _ hormones , asparaginase , clofibrate , estrogens and estrogen - containing _ compounds , 5 - fluorouracil , furosemide , glucocorticoids , meclofenamic _ acid , mefenamic _ acid , methadone , perphenazine , phenylbutazone , <e20> drug2 </e20> , salicylates , tamoxifen .
mechanism	aspirin : concomitant <e11> drug1 </e11> may decrease the metabolic clearance of <e20> drug2 </e20> .
mechanism	blood levels of hydro drug1 increased 24 % when <e10> drug1 </e10> was coadministered with <e20> drug2 </e20> ( nonselective inhibitor of cytochrome p - 450 ) for # days , and decreased 28 % with coadministration of rifampin ( potent inducer of cytochrome p - 450 ) for # days .
mechanism	anticonvulsants ( carbamazepine , felbamate , phenobarbital , <e10> drug1 </e10> , topiramate ) : increase the metabolism of ethinyl _ estradiol and / or some <e22> drug2 </e22> , leading to possible decrease in contraceptive effectiveness .
mechanism	phenobarbital ( primidone ) : population pharmacokinetic analyses indicate that <e10> drug1 </e10> clearance is 60 % greater in patients taking phenobarbital ( <e20> drug2 </e20> ) with or without other enzyme - inducing aeds .
mechanism	agents with increased levels in the presence of carbamazepine : <e11> drug1 </e11> increases the plasma levels of the following agents : <e20> drug2 </e20> , phenytoin ( 6 ) , and primidone thus , if a patient has been titrated to a stable dosage on one of the agents in this category , and then begins a course of the treatment with drug1 , it is reasonable to expect that a dose decrease for the concomitant agent may be necessary .
mechanism	particular caution should be observed with digitalis _ preparations since there are conflicting results for the effect of <e10> drug1 </e10> on the availability of <e20> drug2 </e20> and digitoxin .
mechanism	agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of <e11> drug1 </e11> are the following : <e20> drug2 </e20> , doxorubicin _ hcl , felbamate , rifampin , phenobarbital , phenytoin ( 2 ) , primidone , methsuximide , and theophylline thus , if a patient has been titrated to a stable dosage on drug1 , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for drug1 may be necessary .
mechanism	oral contraceptives : <e10> drug1 </e10> , when given once daily for # days as a 100 - mg capsule with an oral contraceptive containing # mcg of ethinyl _ estradiol and # mg of <e20> drug2 </e20> , decreased the auc of ethinyl _ estradiol by 43 % , and decreased the auc of drug2 by 8 % ;
mechanism	inducers and inhibitors of hepatic metabolism : <e10> drug1 </e10> reduced plasma concentrations of <e20> drug2 </e20> by about 70 % .
